UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
For the quarterly period ended
OR
For the transition period from _______ to _______
Commission File Number:
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
(Former address of principal executive offices) (Zip Code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each Class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant (1)
has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.
Indicate by check mark whether the registrant has
submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of
this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| ☒ | Smaller reporting company | ||
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a
shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐
No
As of May 15, 2025, there were shares of common stock, par value $ per share, outstanding.
TABLE OF CONTENTS
| i |
On October 21, 2024, the Company’s stockholders approved a reverse stock split of the Company’s common stock, with a par value of $0.001 per share (the “Common Stock”), at a ratio of not less than 1-for-2 and not more than 1-for-24, subject to the Company’s board of directors’ (the “Board”) authority to determine the ratio, and on October 23, 2024, the Board approved a 1-for-24 reverse stock split of the Common Stock, which became effective on November 12, 2024 (the “Reverse Stock Split”). As a result of the Reverse Stock Split, each of the twenty-four pre-split shares of the Common Stock outstanding automatically combined and converted to one issued and outstanding share of the Common Stock without any action on the part of the stockholders. Unless otherwise indicated, all share amounts and per share amounts in this report have been presented to give effect to the 1-for-24 reverse stock split of the shares of the Common Stock.
| ii |
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
SHINECO, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
| ASSETS | ||||||||
| March 31, | June 30, | |||||||
| 2025 | 2024 | |||||||
| (Unaudited) | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Accounts receivable, net | ||||||||
| Due from related parties, net | ||||||||
| Inventories, net | ||||||||
| Advances to suppliers, net | ||||||||
| Other current assets, net | ||||||||
| Current assets held for discontinued operations | ||||||||
| TOTAL CURRENT ASSETS | ||||||||
| Property and equipment, net | ||||||||
| Intangible assets, net | ||||||||
| Goodwill | ||||||||
| Operating lease right-of-use assets | ||||||||
| Non-current assets held for discontinued operations | ||||||||
| TOTAL ASSETS | $ | $ | ||||||
| LIABILITIES AND EQUITY | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Short-term loans | $ | $ | ||||||
| Accounts payable | ||||||||
| Advances from customers | ||||||||
| Due to related parties | ||||||||
| Other payables and accrued expenses | ||||||||
| Operating lease liabilities - current | ||||||||
| Convertible note payable | ||||||||
| Deferred income | ||||||||
| Taxes payable | ||||||||
| Current liabilities held for discontinued operations | ||||||||
| TOTAL CURRENT LIABILITIES | ||||||||
| Income tax payable - noncurrent portion | ||||||||
| Operating lease liabilities - non-current | ||||||||
| Convertible note payable - non-current | ||||||||
| Deferred tax liability | ||||||||
| Non-current liabilities held for discontinued operations | ||||||||
| TOTAL LIABILITIES | ||||||||
| Commitments and contingencies | ||||||||
| EQUITY: | ||||||||
| Common stock; par value $, shares authorized; | ||||||||
| and shares issued and outstanding at March 31, 2025 and June 30, 2024* | ||||||||
| Additional paid-in capital | ||||||||
| Subscription receivable | ( | ) | ||||||
| Subscribed common stock | ||||||||
| Statutory reserve | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Accumulated other comprehensive loss | ( | ) | ( | ) | ||||
| Total Stockholders’ equity of Shineco, Inc. | ||||||||
| Non-controlling interest | ||||||||
| TOTAL EQUITY | ||||||||
| TOTAL LIABILITIES AND EQUITY | $ | $ | ||||||
| * |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| 1 |
SHINECO, INC.
CONDENSED CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
(Unaudited)
For the Nine Months Ended March 31, | For the Three Months Ended March 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| REVENUE | $ | $ | $ | $ | ||||||||||||
| COST OF REVENUE | ||||||||||||||||
| Cost of products | ||||||||||||||||
| Business and sales related tax | ||||||||||||||||
| Total cost of revenue | ||||||||||||||||
| GROSS INCOME (LOSS) | ( | ) | ||||||||||||||
| OPERATING EXPENSES | ||||||||||||||||
| General and administrative expenses | ||||||||||||||||
| Selling expenses | ||||||||||||||||
| Research and development expenses | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| LOSS FROM OPERATIONS | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| OTHER INCOME (EXPENSE) | ||||||||||||||||
| Gain from disposal of a subsidiary | ||||||||||||||||
| Other income, net | ||||||||||||||||
| Amortization of debt issuance costs | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Interest expenses, net | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Total other expenses | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| LOSS BEFORE PROVISION FOR INCOME TAXES FROM CONTINUING OPERATIONS | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| BENEFIT FOR INCOME TAXES | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| NET LOSS FROM CONTINUING OPERATIONS | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| DISCONTINUED OPERATIONS: | ||||||||||||||||
| Loss from discontinued operations, net of taxes | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Income from disposal of discontinued operations | ||||||||||||||||
| Net income (loss) from discontinued operations | ( | ) | ( | ) | ( | ) | ||||||||||
| NET LOSS | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Net loss attributable to non-controlling interest | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| NET LOSS ATTRIBUTABLE TO SHINECO, INC. | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| COMPREHENSIVE LOSS | ||||||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Other comprehensive income (loss): foreign currency translation income (loss) | ( | ) | ||||||||||||||
| Total comprehensive loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Less: comprehensive loss attributable to non-controlling interest | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| COMPREHENSIVE LOSS ATTRIBUTABLE TO SHINECO, INC. | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average number of shares basic and diluted | ||||||||||||||||
| Basic and diluted loss per common share | $ | ) | $ | ) | $ | ) | $ | ) | ||||||||
| Earnings (loss) per common share | ||||||||||||||||
| Continuing operations - Basic and Diluted | ) | ) | ) | ) | ||||||||||||
| Discontinued operations - Basic and Diluted | ) | ) | ) | |||||||||||||
| Net loss per common share - basic and diluted | ) | ) | ) | ) | ||||||||||||
* Retrospectively restated for effect of the Reverse Stock Split on November 12, 2024.
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements
| 2 |
SHINECO, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
FOR THE NINE MONTHS ENDED MARCH 31, 2025 AND 2024
(UNAUDITED)
| ACCUMULATED | ||||||||||||||||||||||||||||||||||||||||
| COMMON | ADDITIONAL | OTHER | NON- | |||||||||||||||||||||||||||||||||||||
| COMMON STOCK | SUBSCRIPTION | STOCK |
PAID-IN | STATUTORY | ACCUMULATED | COMPREHENSIVE | CONTROLLING | TOTAL | ||||||||||||||||||||||||||||||||
| SHARES* | AMOUNT | RECEIVABLE | SUBSCRIBED | CAPITAL | RESERVE | DEFICIT | LOSS | INTEREST | EQUITY | |||||||||||||||||||||||||||||||
| Balance at June 30, 2023 | $ | $ | ( | ) | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | |||||||||||||||||||||||||
| Acquisition of Wintus | ( | ) | ||||||||||||||||||||||||||||||||||||||
| Disposal of Tenet-Jove | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||
| Stock issuance | ||||||||||||||||||||||||||||||||||||||||
| Effect of rounding fractional shares into whole shares upon Reverse Stock Split | ( | ) | ||||||||||||||||||||||||||||||||||||||
| Proceeds received from investors for subscription of common stock | - | |||||||||||||||||||||||||||||||||||||||
| Forgiveness of subscription receivable | - | |||||||||||||||||||||||||||||||||||||||
| Issuance of common shares for convertible notes redemption | ||||||||||||||||||||||||||||||||||||||||
| Common stock issued for management and employees | ||||||||||||||||||||||||||||||||||||||||
| Net loss from continuing operations for the period | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||
| Net income (loss) from discontinued operation for the period | - | ( | ) | |||||||||||||||||||||||||||||||||||||
| Foreign currency translation gain (loss) | - | ( | ) | |||||||||||||||||||||||||||||||||||||
| Balance at March 31, 2024 | $ | $ | ( | ) | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | |||||||||||||||||||||||||
| Balance at June 30, 2024 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | |||||||||||||||||||||||||||
| Stock issuance | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
| Effect of rounding fractional shares into whole shares upon Reverse Stock Split | ( | ) | ||||||||||||||||||||||||||||||||||||||
| Issuance of common shares for convertible notes redemption | ||||||||||||||||||||||||||||||||||||||||
| Common stock issued for management and employees | ||||||||||||||||||||||||||||||||||||||||
| Net loss from continuing operations for the year | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||
| Net loss from discontinued operation for the period | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||
| Foreign currency translation gain | - | |||||||||||||||||||||||||||||||||||||||
| Balance at March 31, 2025 | $ | $ | ( | ) | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | |||||||||||||||||||||||||
| * |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| 3 |
SHINECO, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024
(UNAUDITED)
| COMMON | ADDITIONAL | ACCUMULATED OTHER | NON- | |||||||||||||||||||||||||||||||||||||
| COMMON STOCK | SUBSCRIPTION | STOCK | PAID-IN | STATUTORY | ACCUMULATED | COMPREHENSIVE | CONTROLLING | TOTAL | ||||||||||||||||||||||||||||||||
| SHARES* | AMOUNT | RECEIVABLE | SUBSCRIBED | CAPITAL | RESERVE | DEFICIT | LOSS | INTEREST | EQUITY | |||||||||||||||||||||||||||||||
| Balance at December 31, 2023 | $ | $ | ( | ) | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | |||||||||||||||||||||||||
| Effect of rounding fractional shares into whole shares upon Reverse Stock Split | ( | ) | ||||||||||||||||||||||||||||||||||||||
| Proceeds received from investors for subscription of common stock | - | |||||||||||||||||||||||||||||||||||||||
| Net loss from continuing operations for the period | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||
| Net loss from discontinued operation for the period | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||
| Foreign currency translation loss | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||
| Balance at March 31, 2024 | $ | $ | ( | ) | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | |||||||||||||||||||||||||
| Balance at December 31, 2024 | $ | $ | ( | ) | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | |||||||||||||||||||||||||
| Stock issuance | ( | ) | ||||||||||||||||||||||||||||||||||||||
| Issuance of common shares for convertible notes redemption | ||||||||||||||||||||||||||||||||||||||||
| Net loss from continuing operations for the period | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||
| Net loss from discontinued operation for the period | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||
| Foreign currency translation loss | - | |||||||||||||||||||||||||||||||||||||||
| Balance at March 31, 2025 | $ | $ | ( | ) | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | |||||||||||||||||||||||||
| * |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| 4 |
SHINECO, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
| For the Nine Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Net income (loss) from discontinued operations, net of tax | ( | ) | ||||||
| Net loss from continuing operations | ( | ) | ( | ) | ||||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | ||||||||
| Allowance for (net recovery of) credit losses and doubtful accounts | ( | ) | ||||||
| Reversal of inventory reserve | ( | ) | ( | ) | ||||
| Deferred tax benefit | ( | ) | ( | ) | ||||
| Gain from disposal of a subsidiary | ( | ) | ||||||
| Amortization of right of use assets | ||||||||
| Forgiveness of subscription receivable | ||||||||
| Common stock issued for management and employees | ||||||||
| Amortization of debt issuance and other costs | ||||||||
| Accrued interest expense for convertible notes | ||||||||
| Accrued interest expense for loans and others | ||||||||
| Accrued interest income from third parties | ( | ) | ( | ) | ||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | ||||||||
| Advances to suppliers | ( | ) | ||||||
| Inventories | ||||||||
| Other current assets | ( | ) | ( | ) | ||||
| Accounts payable | ( | ) | ( | ) | ||||
| Contract liabilities | ( | ) | ||||||
| Deferred income | ||||||||
| Other payables and accrued expenses | ||||||||
| Other long-term payable | ( | ) | ||||||
| Operating lease liabilities | ( | ) | ( | ) | ||||
| Taxes payable | ( | ) | ( | ) | ||||
| Net cash used in operating activities from continuing operations | ( | ) | ( | ) | ||||
| Net cash used in operating activities from discontinued operations | ( | ) | ( | ) | ||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Acquisitions of property and equipment | ( | ) | ||||||
| Payment made for loans to third parties | ( | ) | ( | ) | ||||
| Repayment from loan to third parties | ||||||||
| Repayments of loans to related parties | ( | ) | ||||||
| Investment in unconsolidated entity | ( | ) | ||||||
| Prepayment for business acquisition | ( | ) | ||||||
| Disposal of a subsidiary, net of cash | ( | ) | ||||||
| Disposal of VIEs - Tenet-Jove, net of cash | ( | ) | ||||||
| Net cash used in investing activities from continuing operations | ( | ) | ( | ) | ||||
| Net cash used in investing activities from discontinued operations | ( | ) | ||||||
| Net cash used in by investing activities | ( | ) | ( | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from short-term loans | ||||||||
| Repayment of short-term loans | ( | ) | ||||||
| Proceeds from loan from third party | ||||||||
| Repayment of loan from third party | ( | ) | ||||||
| Repayment of convertible note | ( | ) | ||||||
| Proceeds from issuance of common stock | ||||||||
| Proceeds received from investors for subscription of common stock | ||||||||
| Proceeds from (repayments of) advances from related parties | ( | ) | ||||||
| Net cash provided by financing activities from continuing operations | ||||||||
| Net cash provided by (used in) financing activities from discontinued operations | ( | ) | ||||||
| Net cash provided by financing activities | ||||||||
| EFFECT OF EXCHANGE RATE CHANGE ON CASH AND CASH EQUIVALENTS | ||||||||
| NET DECREASE IN CASH AND CASH EQUIVALENTS | ( | ) | ( | ) | ||||
| CASH AND CASH EQUIVALENTS - Beginning of the period | ||||||||
| CASH AND CASH EQUIVALENTS - End of the period | $ | $ | ||||||
| Less: cash and cash equivalents of discontinued operations - Ended of the period | ||||||||
| Cash and cash equivalents of continuing operations - Ended of the period | $ | $ | ||||||
| SUPPLEMENTAL CASH FLOW DISCLOSURES: | ||||||||
| Cash paid for interest | $ | $ | ||||||
| SUPPLEMENTAL NON-CASH OPERATING, INVESTING AND FINANCING ACTIVITIES: | ||||||||
| Issuance of common shares for convertible notes redemption | $ | $ | ||||||
| Issuance of common shares for proceeds received in prior year | $ | $ | ||||||
| Issuance of common shares for business acquisition | $ | $ | ||||||
| Transferal of equity interest of Tenet Jove for business acquisition of Wintus | $ | $ | ||||||
| Right-of-use assets obtained in exchange for operating lease obligations | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| 5 |
NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS
Shineco, Inc. (“Shineco” or the “Company”) was incorporated in the State of Delaware on August 20, 1997. The Company is a holding company whose primary purpose is to develop business opportunities in the People’s Republic of China (the “PRC” or “China”).
On December 30, 2004, the Company acquired all of
the issued and outstanding shares of Beijing Tenet-Jove Technological Development Co., Ltd. (“Tenet-Jove”), a PRC company,
in exchange for restricted shares of the Company’s common stock, and the sole operating business of the Company became that of its
subsidiary, Tenet-Jove. Tenet-Jove was incorporated on December 15, 2003 under the laws of China. Consequently, Tenet-Jove became a
On December 31, 2008, June 11, 2011, and May 24, 2012, Tenet-Jove entered into a series of contractual agreements including an Executive Business Cooperation Agreement, a Timely Reporting Agreement, an Equity Interest Pledge Agreement, and an Executive Option Agreement (collectively, the “VIE Agreements”), with each one of the following entities, Ankang Longevity Pharmaceutical (Group) Co., Ltd. (“Ankang Longevity Group”), Yantai Zhisheng International Freight Forwarding Co., Ltd. (“Zhisheng Freight”) and Qingdao Zhihesheng Agricultural Produce Services., Ltd. (“Qingdao Zhihesheng”). On February 24, 2014, Tenet-Jove entered into the same series of contractual agreements with Shineco Zhisheng (Beijing) Bio-Technology Co., Ltd. (“Zhisheng Bio-Tech”), which was incorporated in 2014. Zhisheng Bio-Tech, Zhisheng Freight and Qingdao Zhihesheng are collectively referred to herein as the “Zhisheng VIEs.”
Pursuant to the VIE Agreements, Tenet-Jove had the exclusive right to provide to the Zhisheng VIEs and Ankang Longevity Group consulting services related to their business operations and management. All the above contractual agreements obligated Tenet-Jove to absorb a majority of the risk of loss from the Zhisheng VIEs and Ankang Longevity Group’s activities and entitled Tenet-Jove to receive a majority of their residual returns. In essence, Tenet-Jove became the primary beneficiary of the operations of the Zhisheng VIEs and Ankang Longevity Group. Therefore, the Zhisheng VIEs and Ankang Longevity Group were treated as variable interest entities (“VIEs”) under the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810 “Consolidation.” Accordingly, the accounts of these entities are consolidated with those of Tenet-Jove.
Since Shineco was effectively controlled by the majority
shareholders of the Zhisheng VIEs and Ankang Longevity Group, Shineco owns
On September 30, 2017, Tenet-Jove established Xinjiang
Shineco Taihe Agriculture Technology Ltd. (“Xinjiang Taihe”) with registered capital of RMB
On December 10, 2016, Tenet-Jove entered
into a purchase agreement with Tianjin Tajite E-Commerce Co., Ltd. (“Tianjin Tajite”), an online e-commerce company based
in Tianjin, China, specializing in distributing Luobuma related products and branded products of Daiso 100-yen shops, pursuant to which
Tenet-Jove would acquire a
| 6 |
On March 13, 2019, Tenet-Jove established Beijing
Tenjove Newhemp Biotechnology Co., Ltd. (“TNB”) with registered capital of RMB
On July 23, 2020, Shanghai Jiaying International Trade
Co., Ltd. (“Shanghai Jiaying”) was established with registered capital of RMB
On January 7, 2021, Inner Mongolia Shineco Zhonghemp
Biotechnology Co., Ltd. (“SZB”) was established with registered capital of RMB
On June 8, 2021, Tenet-Jove entered into a Restructuring Agreement with various parties. Pursuant to the terms of the Restructuring Agreement, (i) the Company transferred all of its rights and interests in Ankang Longevity to the Shareholders of Yushe County Guangyuan Forest Development Co., Ltd. (“Guangyuan”) in exchange for the control of 100% of equity interests and assets in Guangyuan; (ii) Tenet-Jove entered a Termination Agreement with Ankang Longevity and the Ankang Shareholders; (iii) as a consideration to the Restructuring Agreement and based on a valuation report on the equity interests of Guangyuan issued by an independent third party, Tenet-Jove relinquished all of its rights and interests in Ankang Longevity and transferred those rights and interests to the Guangyuan Shareholders; and (iv) Guangyuan and the Guangyuan Shareholders entered into a series of variable interest entity agreements with Tenet-Jove. After signing the Restructuring Agreement, the Company and the shareholders of Ankang and Guangyuan actively carried out the transferring of rights and interests in Ankang and Guangyuan, and the transferring was completed subsequently on July 5, 2021. Afterwards, with the completion of all other follow-ups works, on August 16, 2021, the Company, through its subsidiary Tenet-Jove, completed the previously announced acquisition pursuant to the Restructuring Agreement dated June 8, 2021.
On December 7, 2021, the Company established Shineco
Life Science Research Co., Ltd. (“Life Science”) as a wholly foreign-owned entity with registered capital of US$
On April 13, 2022, the Company established Shineco
Life Science Group Hong Kong Co., Limited (“Shineco Life”) as a wholly owned entity with registered capital of US$
On May 16, 2023, Fuzhou Meida Health Management Co.,
Ltd (“Fuzhou Meida”), formerly known as Pangke Planet (Fuzhou) Health Management Co., Ltd, was established with registered
capital of RMB
On May 16, 2023, Shinkang Technology (Jiangsu) Co.,
Ltd (“Shinkang”) was established with registered capital of RMB
On May 23, 2023, Life Science established Beijing
Shineco Chongshi Information Consulting Co., Ltd (“Chongshi”) as a wholly owned entity with registered capital of RMB
| 7 |
On December 30, 2022, Shineco Life closed the acquisition
of
On May 29, 2023, Shineco Life entered into a stock
purchase agreement with Dream Partner Limited, a BVI corporation (“Dream Partner”), Chongqing Wintus Group, a corporation
incorporated under the laws of mainland China (“Wintus”), and certain shareholders of Dream Partner (the “Wintus Sellers”),
pursuant to which Shineco Life shall acquire
On January 9, 2025, Shineco Life established Beijing
Shineco Chonggao Technology Co., Ltd. (“Chonggao”) as a wholly foreign-owned entity with registered capital of RMB
On March 20, 2025, Shineco Life entered into a stock
purchase agreement with Yi Yang (the “Seller”), a current and only shareholder of FuWang (HK) International Company Limited
(“FuWang (HK)”), a company limited by shares incorporated in Hong Kong. Pursuant to the agreement, the Seller sold
The Company, through its subsidiaries, currently operates two main business segments: 1) Biowin specializes in the development, production and distribution of innovative rapid diagnostic products and related medical devices for the most common diseases (“Rapid Diagnostic and Other Products”); and (2) Fuzhou Meida operates a health-oriented chain restaurant that specializes in developing healthy meals for people with slow metabolic health and those in recovery from metabolic disorders. Due to the Wintus Acquisition and FuWang Acquisition mentioned above, the Company’s business segments, that were operated by Tenet-Jove and its subsidiaries, Guangyuan and Zhisheng VIEs which Tenet-Jove is the primary beneficiary of (the “Tenet-Jove Disposal Group”) and Wintus, are classified as discontinued operations on the Company’s unaudited condensed consolidated financial statements. These business segments are: 1) Tenet-Jove is engaged in manufacturing and selling Bluish Dogbane and related products, also known in Chinese as “Luobuma,” including therapeutic clothing and textile products made from Luobuma; 2) Qingdao Zhihesheng and Guangyuan are engaged in planting, processing, and distributing green agricultural produce; (“Agricultural Products”); 3) Zhisheng Freight is providing domestic and international logistic services (“Freight Services”); and 4) Wintus is engaged in producing, processing and distribution of agricultural products, such as silk and silk fabrics as well as trading of fresh fruit (“Other Agricultural Products”).
| 8 |
NOTE 2. GOING CONCERN
As disclosed in the Company’s unaudited condensed
consolidated financial statements, the Company had recurring net losses from continuing operations of US$
Despite those negative financial trends, as of March 31, 2025, the Company had taken the following actions to enhance the Company’s liquidity:
| 1) | On June 20, 2024, the Company entered into a securities purchase agreement with certain non-U.S. investors (the “June 2024 Purchasers”), pursuant to which the Company agreed to sell, and the Purchasers agreed to purchase, severally and not jointly, an aggregate of shares of common stock of the Company (the “June 2024 Shares”) at an offering price of US$ per share for gross proceeds of up to US$ |
| 2) | On July 11, 2024, the Company entered into an Underwriting Agreement with EF Hutton LLC, as the representative for several underwriters, relating to the underwritten public offering (the “Offering”) of shares of common stock at a public offering price of US$ per share, for aggregate gross proceeds of approximately US$ |
| 3) | On August 22, 2024, the Company entered into a securities purchase agreement (the “SPA”) with 22 purchasers, each an unrelated third party to the Company (collectively, the “August 2024 Purchasers”). Pursuant to the SPA, the August 2024 Purchasers agree to purchase, and the Company agreed to issue and sell to the August 2024 Purchasers, an aggregate of shares of the Company’s common stock, par value US$ per share (the “August 2024 Shares”), at a purchase price of US$ per share, and for an aggregate purchase price of US$ |
| 4) | On December 24, 2024, the
Company entered into a securities purchase agreement with nine non-U.S. investors (the “Purchasers”), pursuant to which
the Company agreed to sell, and the December 2024 Purchasers agreed to purchase, severally and not jointly, an aggregate of
shares of common stock of the Company (the “Shares”) at a purchase price of US$
per share for gross proceeds of US$ |
Management believes that the foregoing measures collectively will provide sufficient liquidity for the Company to meet its future liquidity needs for at least the 12 months following the date of this filing.
| 9 |
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation and Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information pursuant to the rules of the SEC and have been consistently applied. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of results for the full year. These financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Form 10-K for the fiscal year ended June 30, 2024, which was filed on September 30, 2024.
The unaudited condensed consolidated financial statements
include the financial statements of the Company and its subsidiaries, for which the Company is the primary beneficiary, including the
Hong Kong-registered entities and PRC-registered entities owned by the Company. The results of subsidiaries acquired or disposed of are
recorded in the unaudited condensed consolidated income statements from the effective date of acquisition or up to the effective date
of disposal, as appropriate.
Consolidation of Variable Interest Entities
VIEs are generally entities that lack sufficient equity to finance their activities without additional financial support from other parties or whose equity holders lack adequate decision-making ability. All VIEs and their subsidiaries with which the Company is involved must be evaluated to determine the primary beneficiary of the risks and rewards of the VIE. The primary beneficiary is required to consolidate the VIE for financial reporting purposes.
There are no consolidated assets of the VIEs and the VIEs’ subsidiaries that are collateral for the obligations of the VIEs and the VIEs’ subsidiaries and can only be used to settle the obligations of the VIEs and the VIEs’ subsidiaries.
As the VIEs are incorporated as limited liability companies under the PRC Company Law, creditors or beneficial interest holders of the VIEs do not have recourse to the general credit of the Company for any of the liabilities of the VIEs in normal course of business.
There are no terms in any arrangements, considering both explicit arrangements and implicit variable interests that require the Company or its subsidiaries to provide financial support to the VIEs and the VIEs’ subsidiaries. However, if the VIEs and the VIEs’ subsidiaries ever need financial support, the Company or its subsidiaries may, at their option and subject to statutory limits and restrictions, provide financial support to the VIEs and the VIEs’ subsidiaries through loans to the shareholder of the VIEs and the VIEs’ subsidiaries or entrustment loans to the VIEs and the VIEs’ subsidiaries.
The carrying amount of the VIEs and their subsidiaries’ consolidated income information held for discontinued operations were as follows:
| For the nine months ended March 31, | For the three months ended March 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Income from operations | $ | $ | $ | $ | ||||||||||||
| Net income | $ | $ | $ | $ | ||||||||||||
| 10 |
Non-controlling Interests
U.S. GAAP requires that non-controlling interests in subsidiaries and affiliates be reported in the equity section of a company’s balance sheet. In addition, the amounts attributable to the non-controlling interests in the net loss of these entities are reported separately in the unaudited condensed consolidated statements of loss and comprehensive loss.
Risks and Uncertainties
The operations of the Company are located in the PRC and are subject to special considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic, and legal environment and foreign currency exchange. The Company’s results may be adversely affected by changes in the political, regulatory, and social conditions in the PRC, and by changes in governmental policies or interpretations with respect to laws and regulations, anti-inflationary measures, currency conversion, remittances abroad, and rates and methods of taxation, among other things. Although the Company has not experienced losses from these factors and believes that it is in compliance with existing laws and regulations, there is no guarantee that the Company will continue to do so in the future.
Use of Estimates
The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements as well as the reported amounts of revenue and expenses during the reporting periods. Significant estimates required to be made by management include, but are not limited to, useful lives of property and equipment, and intangible assets, the recoverability of long-lived assets, assessment of expected credit losses for accounts receivable and other current asset, the valuation allowance of deferred taxes, and inventory reserves. Actual results could differ from those estimates.
Revenue Recognition
The Company generates its revenue primarily through sales of Luobuma products, other agricultural products, healthy meals and rapid diagnostic and other products, as well as providing logistic services and other processing services to external customers in accordance with ASC 606. ASC 606 establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash flows arising from the entity’s contracts to provide goods or services to customers. The core principle requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to be entitled to receive in exchange for those goods or services recognized as performance obligations are satisfied.
With the adoption of ASC 606, “Revenue from Contracts with Customers,” revenue is recognized when all of the following five steps are met: (i) identify the contract(s) with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations; (v) recognize revenue when (or as) each performance obligation is satisfied. The Company has assessed the impact of the guidance by reviewing its existing customer contracts to identify differences that will result from applying the new requirements, including the evaluation of its performance obligations, transaction price, customer payments, transfer of control, and principal versus agent considerations. In accordance with ASC 606, the Company evaluates whether it is appropriate to record the gross amount of product sales and related costs or the net amount earned as commissions. When the Company is a principal, that the Company obtains control of the specified goods or services before they are transferred to the customers, the revenue should be recognized in the gross amount of consideration to which it expects to be entitled in exchange for the specified goods or services transferred. When the Company is an agent and its obligation is to facilitate third parties in fulfilling their performance obligation for specified goods or services, the revenue should be recognized in the net amount for the amount of commission which the Company earns in exchange for arranging for the specified goods or services to be provided by other parties. Based on the assessment, the Company concluded that there was no change to the timing and pattern of revenue recognition for its current revenue streams in scope of Topic 606 and therefore there was no material changes to the Company’s financial statements upon adoption of ASC 606.
| 11 |
More specifically, revenue related to the Company’s products and services is generally recognized as follows:
Sales of products: The Company recognized revenue from the sale of products at the point in time when the goods were delivered and title to the goods passed to the customer, provided that there were no uncertainties regarding customer acceptance; persuasive evidence of an arrangement existed; the sales price was fixed or determinable; and collectability was deemed probable.
Revenue from the provision of services: The Company merely acts as an agent in these types of services transactions. Revenue from domestic air and overland freight forwarding services was recognized at the point in time upon the performance of services as stipulated in the underlying contract or when commodities were being released from the customer’s warehouse; the service price was fixed or determinable; and collectability was deemed probable.
Cash and Cash Equivalents
Cash and cash equivalents consist of cash on hand,
cash on deposit, and other highly liquid investments which are unrestricted as to withdrawal or use, and which have original maturities
of three months or less when purchased. The Company maintains cash with various financial institutions mainly in the PRC. As of March
31, 2025 and June 30, 2024, the Company had
Under PRC laws, it is generally required that a commercial bank in the PRC that holds third-party cash deposits protect the depositors’ rights over and interests in their deposited money. PRC banks are subject to a series of risk control regulatory standards, and PRC bank regulatory authorities are empowered to take over the operation and management of any PRC bank that faces a material credit crisis. Company monitors the respective financial institutions where they maintain their cash with and has not experienced any problems.
Accounts Receivable, Net
Accounts receivable are recorded at net realizable
value, consisting of the carrying amount less an allowance for credit losses, as necessary. As of March 31, 2025 and June 30, 2024, the
allowance for credit losses from the continuing operations was US$
Advances to Suppliers, Net
Advances to suppliers consist of payments to suppliers
for materials that have not been received. As of March 31, 2025 and June 30, 2024, the allowance for uncollectible advances to suppliers
from the continuing operations was US$
Credit Losses
On July 1, 2023, the Company adopted Accounting Standards Update 2016-13 “Financial Instruments – Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments,” which replaces the incurred loss methodology with an expected loss methodology that is referred to as the current expected credit loss (“CECL”) methodology. The adoption of the credit loss accounting standard has no material impact on the Company’s consolidated financial statements as of the adoption date.
The Company’s account receivables and other receivables included in other current assets on the unaudited condensed consolidated balance sheets are within the scope of ASC Topic 326. The Company makes estimates of expected credit and collectability trends for the allowance for credit losses based upon assessment of various factors, including historical experience, the age of the accounts receivable and other receivables balances, credit-worthiness of the customers and other debtors, current economic conditions, reasonable and supportable forecasts of future economic conditions, and other factors that may affect its ability to collect from the customers and other debtors. The Company also provides specific provisions for allowance when facts and circumstances indicate that the receivable is unlikely to be collected.
| 12 |
ASC Topic 326 is also applicable to loans to third parties that are included in the other current assets on the unaudited condensed consolidated balance sheets. Management estimates the allowance for credit losses on loans that do not share similar risk characteristics on an individual basis. The key factors considered when determining the above allowances for credit losses include estimated loan collection schedule, discount rate, and assets and financial performance of the borrowers.
Expected credit losses are recorded as general and administrative expenses on the unaudited condensed consolidated statements of loss and comprehensive loss. After all attempts to collect a receivable have failed, the receivable is written off against the allowance. In the event the Company recovers amount previously reserved, the Company will reduce the specific allowance for credit losses.
Inventories, Net
Inventories, which are stated at the lower of cost
or net realizable value, consist of raw materials, work-in-progress, and finished goods related to the Company’s products. Net realizable
value is the estimated selling price in the normal course of business less any costs to complete and sell products. Cost is determined
using the weighted average method. The Company periodically evaluates its inventory and records an inventory reserve for certain inventories
that may not be saleable or whose cost exceeds net realizable value. As of March 31, 2025 and June 30, 2024, the inventory reserve from
the continuing operations was and US$
Business Acquisitions
Business acquisitions are accounted for under the acquisition method. The acquisition method requires the reporting entity to identify the acquirer, determine the acquisition date, recognize and measure the identifiable assets acquired, the liabilities assumed and any non-controlling interest in the acquired entity, and recognize and measure goodwill or a bargain gain from the purchase. The acquiree’s results are included in the Company’s consolidated financial statements from the date of acquisition. Assets acquired and liabilities assumed are recorded at their fair values on the date acquired and the excess of the purchase price over the amounts assigned is recorded as goodwill, or if the fair value of the net assets acquired exceeds the purchase price consideration, a bargain purchase gain is recorded. Adjustments to fair value assessments are generally recorded to goodwill over the measurement period (not longer than 12 months). The acquisition method also requires that acquisition-related transaction and post-acquisition restructuring costs be charged to expense as committed, and requires the Company to recognize and measure certain assets and liabilities, including those arising from contingencies and contingent consideration in a business combination.
Goodwill
Goodwill represents the excess of the purchase price over the fair value of assets acquired. The goodwill impairment test compares the fair value of a reporting unit with its carrying amount, including goodwill. If the carrying amount of a reporting unit exceeds its fair value, goodwill of the reporting unit would be considered impaired. To measure the amount of the impairment loss, the implied fair value of a reporting unit’s goodwill is compared to the carrying amount of that goodwill. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. If the carrying amount of a reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. For each of these tests, the fair value of each of the Company’s reporting units is determined using a combination of valuation techniques, including a discounted cash flow methodology. To corroborate the discounted cash flow analysis performed at each reporting unit, a market approach is utilized using observable market data such as comparable companies in similar lines of business that are publicly traded or which are part of a public or private transaction (to the extent available).
| 13 |
Leases
Lessee accounting
The Company follows FASB ASC No. 842, Leases (“Topic 842”). The Company leases office spaces, warehouse, and farmland which are classified as operating leases in accordance with Topic 842. Under Topic 842, lessees are required to recognize the following for all leases (with the exception of short-term leases, usually with initial term of 12 months or less) on the commencement date: (i) lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and (ii) right-of-use (“ROU”) asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term.
Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and includes initial direct costs incurred. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expenses for minimum lease payments are recognized on a straight-line basis over the lease term. All operating lease ROU assets are reviewed for impairment annually. For the nine and three months ended March 31, 2025 and 2024, the Company did not recognize any impairment of its ROU assets.
Lessor accounting
The Company rents out its office to a third party, which is classified as an operating lease in accordance with Topic 842. The revenue from an operating lease is recognized in other income (expenses) in the unaudited condensed consolidated statements of loss and comprehensive loss on a straight-line basis over the term of the lease.
Property and Equipment, Net
Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for additions, major renewals, and betterments are capitalized, and expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is provided on a straight-line basis, less estimated residual value, if any, over an asset’s estimated useful life. Farmland leasehold improvements are amortized over the shorter of lease term or estimated useful lives of the underlying assets. The estimated useful lives of the Company’s property and equipment are as follows:
| Estimated useful lives | ||
| Buildings | ||
| Machinery and equipment | ||
| Motor vehicles | ||
| Office equipment | ||
| Farmland leasehold improvements | ||
| Fixture and furniture |
Construction in progress includes property and equipment in the course of construction for production or for its own use purposes. Construction in progress is carried at cost less any recognized impairment loss. Construction in progress is classified to the appropriate category of property and equipment when completed and ready for intended use. Depreciation of these assets, on the same basis as other property assets, commences when the assets are ready for their intended use.
| 14 |
Land Use Rights, Net
According to Chinese laws and regulations regarding land use rights, land in urban districts is owned by the State, while land in the rural areas and suburban areas, except otherwise provided for by the State, is collectively owned by individuals designated as resident farmers by the State. In accordance with the legal principle that land ownership is separate from the right to the use of the land, the government grants individuals and companies the rights to use parcels of land for a specified period of time. Land use rights, which are usually prepaid, are stated at cost less accumulated amortization. Amortization is provided over the life of the land use rights, using the straight-line method. The useful life is 50 years, based on the terms of the land use rights.
Long-lived Assets
Finite-lived assets and intangibles are reviewed for impairment testing when circumstances require. For purposes of evaluating the recoverability of long-lived assets, when undiscounted future cash flows will not be sufficient to recover an asset’s carrying amount, the asset is written down to its fair value. The long-lived assets of the Company that are subject to evaluation consist primarily of property and equipment, land use rights, ROU assets and investments. For the nine and three months ended March 31, 2025 and 2024, the Company did not recognize any impairment of its long-lived assets.
Derivative Financial Assets
Derivative financial assets are measured at fair value and recognized as either assets or liabilities on the unaudited condensed consolidated balance sheets in either other current or non-current assets or other current liabilities or non-current liabilities, depending upon maturity and commitment. Changes in the fair value of derivatives are either recognized periodically in the unaudited condensed consolidated statements of loss and comprehensive loss, depending on the use of the derivatives and whether they qualify for hedge accounting.
The Company selectively uses financial instruments to manage market risk associated with exposure to fluctuations in prices of raw materials for silk products. These financial exposures are monitored and managed by the Company as an integral part of its risk management program. The Company does not engage in derivative instruments for speculative or trading purposes. The Company’s derivative financial assets are not qualified for hedge accounting. Thus, changes in fair value are recognized in “Investment income from derivative financial assets” under discontinued operations in the unaudited condensed consolidated statements of loss and comprehensive loss. The cash flows of derivative financial assets are classified in the same category as the cash flows from the items subject to the economic hedging relationships. The estimated fair value of the derivatives is determined based on relevant market information.
Derivative financial assets are presented as net if rights of setoff exist, with all of the following conditions met: (a) each of the two parties owes the other determinable amounts; (b) the reporting party has the right to set off the amount owed with the amount owed by the other party; (c) the reporting party intends to set off; and (d) the right of setoff is enforceable at law.
The derivative financial assets from the continuing operations were both
nil as of March 31, 2025 and June 30, 2024. The outstanding derivative financial assets from the
discontinued operations as of March 31, 2025 and June 30, 2024 were US$
Fair Value of Financial Instruments
The Company follows the provisions of ASC 820, “Fair Value Measurements and Disclosures.” ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:
| 15 |
Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.
Level 2 applies to assets or liabilities for which there are inputs, other than quoted prices in level, that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the asset or liability.
The carrying value of financial instruments included in current assets and liabilities approximate their fair values because of the short-term nature of these instruments.
Income Taxes
Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the unaudited condensed consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
The provisions of ASC 740-10-25, “Accounting for Uncertainty in Income Taxes,” prescribe a more-likely-than-not threshold for unaudited condensed consolidated financial statement recognition and measurement of a tax position taken (or expected to be taken) in a tax return. This ASC also provides guidance on the recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, accounting for interest and penalties associated with tax positions, and related disclosures. The Company did not have any uncertain tax positions as of March 31, 2025 and June 30, 2024. The Company had not provided deferred taxes for undistributed earnings of non-U.S. subsidiaries as of March 31, 2025, as it is the Company’s policy to indefinitely reinvest these earnings in non-U.S. operations. Quantification of the deferred tax liability, if any, associated with indefinitely reinvested earnings is not practicable.
The statute of limitations for the Company’s U.S. federal income tax returns and certain state income tax returns remains open for tax year 2022 and thereafter. As of March 31, 2025, the tax years ended December 31, 2020 through December 31, 2024 for the Company’s PRC subsidiaries remained open for statutory examination by PRC tax authorities.
On December 22, 2017, the “Tax Cuts and Jobs
Act” (“The Act”) was enacted. Under the provisions of The Act, the U.S. corporate tax rate decreased from
| 16 |
Value-Added Tax
Sales revenue represents the invoiced value of goods,
net of a value-added tax (“VAT”).
Foreign Currency Translation
The Company uses the United States dollar (“U.S. dollars,” “USD,” or “US$”) for financial reporting purposes. The Company’s subsidiaries and VIEs maintain their books and records in their functional currency of Renminbi (“RMB”), the currency of the PRC.
In general, for consolidation purposes, the Company translates the assets and liabilities of its subsidiaries and VIEs into U.S. dollars using the applicable exchange rates prevailing at the balance sheet date, and the statements of income and cash flows are translated at average exchange rates during the reporting periods. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the financial statements of the subsidiaries and VIEs are recorded as accumulated other comprehensive loss.
The balance sheet amounts, with the exception of equity,
as of March 31, 2025 and June 30, 2024 were translated at
Convertible Notes Payable
In accordance with ASC 470 Debt with conversion and other option, an embedded beneficial conversion feature present in a convertible instrument shall be recognized separately at issuance by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital. Issuance costs should be allocated proportionally to the debt host and conversion feature. Deferred financing costs will be discounted and amortized subsequently, and the convertible notes are subsequently carried at amortized cost.
Research and Development Expenses
Research and development costs relating to the development
of new processes and significant improvements and refinements to existing processes are expensed when incurred in accordance with the
FASB ASC 730, “Research and Development.” The research and development costs primarily comprise employee costs, consultant
fees, materials and testing costs, and depreciation to property and equipment used in the research and development activities and other
miscellaneous expenses. For the nine months ended March 31, 2025 and 2024, total research and development expense from continuing operations
were US$
| 17 |
Comprehensive Loss
Comprehensive loss consists of two components, net loss and other comprehensive income (loss). The foreign currency translation gain resulting from translation of the financial statements expressed in RMB to USD is reported in other comprehensive income (loss) in the unaudited condensed consolidated statements of loss and comprehensive loss.
The Company computes loss per share (“EPS”) in accordance with ASC 260, “Earnings per Share” (“ASC 260”). ASC 260 requires companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured as net loss divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., outstanding convertible securities, options, and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. There is no anti-dilutive effect for the nine and three months ended March 31, 2025 and 2024.
| For the nine months ended March 31, | For the three months ended March 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Net loss from continuing operations attributable to Shineco | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Net income (loss) from discontinued operations attributable to Shineco | ( | ) | ( | ) | ( | ) | ||||||||||
| Net loss attributable to Shineco | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Weighted average shares outstanding - basic and diluted* | ||||||||||||||||
| Net loss from continuing operations per share of common share | ||||||||||||||||
| Basic and diluted | $ | ) | $ | ) | $ | ) | $ | ) | ||||||||
| Net earnings (loss) from discontinued operations per share of common share | ||||||||||||||||
| Basic and diluted | $ | ) | $ | $ | ) | $ | ) | |||||||||
| Net loss per share of common share | ||||||||||||||||
| Basic and diluted | $ | ) | $ | ) | $ | ) | $ | ) | ||||||||
| * |
| 18 |
New Accounting Pronouncements
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU requires public entities to disclose significant segment expenses that are regularly provided to the chief operating decision maker (CODM), and an amount and description of other segment items, in both annual and interim periods. The Company’s fiscal year beginning July 1, 2024, is subject to the provisions of ASU 2023-07. As a result, the Company is required to adopt the enhanced segment disclosure requirements beginning with the interim period ending March 31, 2025. While the Company has made significant progress in updating its internal reporting and system processes to comply with the new standard, it was not practicable to complete implementation in time for inclusion in this quarterly report. The Company expects to complete the implementation during the fourth fiscal quarter and will include all required segment disclosures under ASU 2023-07 in its annual report on Form 10-K for the fiscal year ending June 30, 2025.
In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. This ASU requires additional quantitative and qualitative income tax disclosures to enable financial statements users better assess how an entity’s operations and related tax risks and tax planning and operational opportunities affect its tax rate and prospects for future cash flows. The ASU is effective for annual reporting periods beginning after December 15, 2024, with early adoption permitted and can be applied on either a prospective or retroactive basis. The Company plans to adopt this guidance effective July 1, 2025 and the Company is currently evaluating the impact of adopting this ASU on its financial statements.
In March 2024, the FASB issued ASU 2024-01, Compensation - Stock Compensation (Topic 718), Scope Application of Profits Interest and Similar Awards. This standard provides clarity regarding whether profits interest and similar awards are within the scope of Topic 718 of the Accounting Standards Codification. This standard is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company plans to adopt this guidance effective July 1, 2025 and the Company is currently evaluating the impact of adopting this ASU on its financial statements.
In March 2024, the FASB issued ASU No. 2024-02, “Codification Improvements - Amendments to Remove References to the Concepts Statements.” ASU 2024-02 removes references to various FASB Concepts Statements within the Codification. The guidance in ASU No. 2024-02 is effective for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years, and can be applied either prospectively to all new transactions recognized on or after the date that the entity first applies the amendments or retrospectively to the beginning of the earliest comparative period presented in which the amendments were first applied. Early adoption is permitted. The Company plans to adopt this guidance effective July 1, 2025 and the Company is currently evaluating the impact of adopting this ASU on its financial statements.
The Company believes that other recent accounting pronouncement updates will not have a material effect on the Company’s unaudited condensed consolidated financial statements.
NOTE 4 – ACCOUNTS RECEIVABLE, NET
The accounts receivable, net consisted of the following:
| March 31, 2025 | June 30, 2024 | |||||||
| Accounts receivable | $ | $ | ||||||
| Less: allowance for credit losses | ( | ) | ( | ) | ||||
| Accounts receivable, net | ||||||||
| Less: accounts receivable, net held for discontinued operations | ( | ) | ( | ) | ||||
| Accounts receivable, net held for continuing operations | $ | $ | ||||||
Movement of allowance for credit losses is as follows:
| March 31, 2025 | June 30, 2024 | |||||||
| Beginning balance | $ | $ | ||||||
| Acquisition of subsidiaries | ||||||||
| Charge to allowance | ||||||||
| Less: disposal of VIEs | ( | ) | ||||||
| Foreign currency translation adjustments | ||||||||
| Ending balance | $ | $ | ||||||
| 19 |
NOTE 5 – INVENTORIES, NET
The inventories, net consisted of the following:
| March 31, 2025 | June 30, 2024 | |||||||
| Raw materials | $ | $ | ||||||
| Work-in-process | ||||||||
| Finished goods | ||||||||
| Less: inventory reserve | ( | ) | ||||||
| Total inventories, net | ||||||||
| Less: inventories, net, held for discontinued operations | ( | ) | ( | ) | ||||
| Inventories, net, held for continuing operations | $ | $ | ||||||
NOTE 6 – ADVANCES TO SUPPLIERS, NET
The advances to suppliers, net consisted of the following:
| March 31, 2025 | June 30, 2024 | |||||||
| Advances to suppliers | $ | $ | ||||||
| Less: allowance for doubtful accounts | ( | ) | ( | ) | ||||
| Advance to suppliers, net | ||||||||
| Less: advance to supplier, net, held for discontinued operations | ( | ) | ( | ) | ||||
| Advance to supplier, net, held for continuing operations | $ | $ | ||||||
Advances to suppliers consist of mainly payments to suppliers for raw materials or products that have not been received.
Movement of allowance for doubtful accounts is as follows:
| March 31, 2025 | June 30, 2024 | |||||||
| Beginning balance | $ | $ | ||||||
| Acquisition of subsidiaries | ||||||||
| Charge to allowance | ||||||||
| Less: disposal of VIEs | ( | ) | ||||||
| Foreign currency translation adjustments | ( | ) | ||||||
| Ending balance | $ | $ | ||||||
| 20 |
NOTE 7 – OTHER CURRENT ASSETS, NET
Other current assets, net consisted of the following:
| March 31, 2025 | June 30, 2024 | |||||||
| Loans to third parties (1) | $ | $ | ||||||
| Other receivables (2) | ||||||||
| Prepayment for business acquisition (3) | ||||||||
| Short-term deposits | ||||||||
| Prepaid expenses | ||||||||
| Subtotal | ||||||||
| Less: allowance for credit losses | ( | ) | ( | ) | ||||
| Total other current assets, net | ||||||||
| Less: other current assets, net, held for discontinued operations | ( | ) | ( | ) | ||||
| Other current assets, net, held for continuing operations | $ | $ | ||||||
| 1) | |
| 2) | |
| 3) |
| 21 |
Movement of allowance for credit losses is as follows:
| March 31, 2025 | June 30, 2024 | |||||||
| Beginning balance | $ | $ | ||||||
| Acquisition of subsidiaries | ||||||||
| Charge to (reversal of) expense | ( | ) | ||||||
| Less: disposal of VIEs | ( | ) | ||||||
| Foreign currency translation adjustments | ( | ) | ||||||
| Ending balance | $ | $ | ||||||
NOTE 8 - PROPERTY AND EQUIPMENT, NET
Property and equipment, net consisted of the following:
| March 31, 2025 | June 30, 2024 | |||||||
| Buildings | $ | $ | ||||||
| Machinery and equipment | ||||||||
| Motor vehicles | ||||||||
| Office equipment | ||||||||
| Fixture and furniture | ||||||||
| Construction in progress | ||||||||
| Subtotal | ||||||||
| Less: accumulated depreciation and amortization | ( | ) | ( | ) | ||||
| Less: accumulated impairment for property and equipment | ( | ) | ( | ) | ||||
| Total property and equipment, net | ||||||||
| Less: property and equipment, net, held for discontinued operations | ( | ) | ( | ) | ||||
| Property and equipment, net held for continuing operations | $ | $ | ||||||
Depreciation and amortization expense charged to the
continuing operations was US$
Depreciation and amortization expense charged to the
discontinued operations was US$
The Company also provides its customers with specialized
testing devices as its customers could only use these devices to generate results from these rapid diagnostic products. The ownership
of these specialized testing devices is not transferred to its customers, but remains as the Company’s properties. The specialized
testing devices will be returned to the Company when they are no longer required by the customer. As of March 31, 2025 and June 30, 2024,
properties with net book values of US$
| 22 |
On May 29, 2023, the Company’s Board approved
the pledge of real estate property as collateral to guarantee a personal loan of Zhang Yuying, the former chairman of the Board and legal
representative of Tenet-Jove. This collateral was provided in exchange for the transfer of the real estate title from Zhang Yuying to
Chongshi, a subsidiary of the Company. According to the memorandum between the Company and Zhang Yuying, it was anticipated that the loan
would be repaid and the pledge would be released before May 31, 2024. The Company retains the right to claim full compensation if the
property is not released by the due date. On May 24, 2022, Zhang Yuying entered into a loan agreement with Guo Weiqing for a principal
amount of RMB
In addition, the Company also pledged certain property and equipment for the Company’s bank loans and its related party’s personal loan (See Note 12 and Note 13).
NOTE 9 - LAND USE RIGHTS, NET
Land use rights are recognized at cost less accumulated
amortization. According to the Chinese laws and regulations regarding land use rights, land in urban districts is owned by the state,
while land in the rural areas and suburban areas, except otherwise provided for by the state, is collectively owned by individuals designated
as resident farmers by the state. However, in accordance with the legal principle that land ownership is separate from the right to the
use of the land, the government grants the user a “land use right” to use the land. The Company has the land use right to
use the land for
| March 31, 2025 | June 30, 2024 | |||||||
| Land use rights | $ | $ | ||||||
| Less: accumulated amortization | ( | ) | ( | ) | ||||
| Total land use rights, net | ||||||||
| Less: land use rights, net, held for discontinued operations | ( | ) | ( | ) | ||||
| Land use rights, net, held for continuing operations | $ | $ | ||||||
Amortization expense charged to the discontinued operations
was US$
| 23 |
NOTE 10 - LEASES
Lessee
The Company leases offices space and warehouse under
non-cancellable operating leases, with terms ranging from one to seven and a half years. The lease terms vary from
When available, the Company uses the rate implicit in the lease to discount lease payments to present value; however, most of the Company’s leases do not provide a readily determinable implicit rate. Therefore, the Company discounts lease payments based on an estimate of its incremental borrowing rate. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.
The table below presents the operating lease related assets and liabilities held for continuing operations recorded on the balance sheets.
| March 31, 2025 | June 30, 2024 | |||||||
| ROU lease assets | $ | $ | ||||||
| Operating lease liabilities – current | ||||||||
| Operating lease liabilities – non-current | ||||||||
| Total operating lease liabilities | $ | $ | ||||||
The weighted average remaining lease terms and discount rates for all of operating leases held for continuing operations were as follows as of March 31, 2025 and June 30, 2024:
| March 31, 2025 | June 30, 2024 | |||||||
| Remaining lease term and discount rate: | ||||||||
| Weighted average remaining lease term (years) | ||||||||
| Weighted average discount rate | % | % | ||||||
The components of lease expenses for continuing operations were as follows:
| For the nine months ended March 31, | For
the three months ended | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Lease cost: | ||||||||||||||||
| Amortization of right-of-use assets | $ | $ | $ | | $ | |||||||||||
| Interest of operating lease liabilities | ||||||||||||||||
| Total lease cost | $ | $ | $ | $ | ||||||||||||
| 24 |
The table below presents the operating lease related assets and liabilities held for discontinued operations recorded on the balance sheets.
| March 31, 2025 | June 30, 2024 | |||||||
| ROU lease assets | $ | $ | ||||||
| - | ||||||||
| Operating lease liabilities – current | ||||||||
| Operating lease liabilities – non-current | ||||||||
| Total operating lease liabilities | $ | $ | ||||||
The weighted average remaining lease terms and discount rates for all of operating leases held for discontinued operations were as follows as of March 31, 2025 and June 30, 2024:
| March 31, 2025 | June 30, 2024 | |||||||
| Remaining lease term and discount rate: | ||||||||
| Weighted average remaining lease term (years) | - | |||||||
| Weighted average discount rate | % | |||||||
The components of lease expenses for discontinued operations were as follows:
| For the nine months ended March 31, | For the three months ended March 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Lease cost: | ||||||||||||||||
| Amortization of right-of-use assets | $ | $ | $ | $ | | |||||||||||
| Interest of operating lease liabilities | ||||||||||||||||
| Total lease cost | $ | $ | $ | $ | ||||||||||||
Rent expenses totaled US$
Rent expenses totaled US$
The following is a schedule, by years, of maturities of lease liabilities held for continuing operations as of March 31, 2025:
| Remainder of 2025 | $ | |||
| 2026 | ||||
| Total lease payments | ||||
| Less: imputed interest | ( | ) | ||
| Present value of lease liabilities | $ |
| 25 |
Lessor
On September 21, 2023, the
Company’s continuing operations entered into a two-year rental agreement with a third party to lease its property for its
office space. Rental income of US$
NOTE 11 - ACQUISITIONS
Acquisition of Guangyuan
On June 8, 2021, Tenet-Jove entered into a Restructuring
Agreement with various parties. Pursuant to the terms of the Restructuring Agreement, (i) the Company transferred all of its rights and
interests in Ankang Longevity to the Shareholders of Yushe County Guangyuan Forest Development Co., Ltd. (“Guangyuan”) in
exchange for the control of
The management determined that July 5, 2021 was the acquisition date of Guangyuan. The acquisition provides a unique opportunity for the Company to enter the market of planting fast-growing bamboo willows and scenic greening trees.
The transaction was accounted for in accordance with the provisions of ASC 805-10, Business Combinations. The Company retained independent appraisers to advise management in the determination of the fair value of the various assets acquired and liabilities assumed. The values assigned in these financial statements represent management’s best estimate of fair values as of the Acquisition Date.
As required by ASC 805-20, Business Combinations—Identifiable Assets and Liabilities, and Any Non-controlling Interest, management conducted a review to reassess whether they identified all the assets acquired and all the liabilities assumed, and followed ASC 805-20’s measurement procedures for recognition of the fair value of net assets acquired.
The following table summarizes the allocation of estimated fair values of net assets acquired and liabilities assumed:
| Due from related party | $ | |||
| Inventory | ||||
| Other current assets | ||||
| Right of use assets | ||||
| Long-term investments and other non-current assets | ||||
| Other payables and other current liabilities | ( | ) | ||
| Operating lease liabilities | ( | ) | ||
| Total purchase price for acquisition, net of US$ | $ |
Under ASC 805-10, acquisition-related costs (i.e., advisory, legal, valuation and other professional fees) are not included as a component of consideration transferred, but are expensed in the periods in which the costs are incurred. Acquisition-related costs were for the nine and three months ended March 31, 2025 and 2024.
| 26 |
The Company has included the operating results of
Guangyuan in the unaudited condensed consolidated financial statements since the Acquisition Date. in net sales and US$
Acquisition of Biowin
On October 21, 2022, the Company, through its wholly-owned
subsidiary, Shineco Life, entered into a stock purchase agreement with the Seller and Biowin, pursuant to which Shineco Life would acquire
The transaction was accounted for in accordance with the provisions of ASC 805-10, Business Combinations. The Company retained independent appraisers to advise management in the determination of the fair value of the various assets acquired and liabilities assumed. The values assigned in these financial statements represent management’s best estimate of fair values as of the Acquisition Date.
As required by ASC 805-20, Business Combinations—Identifiable Assets and Liabilities, and Any Non-controlling Interest, management conducted a review to reassess whether they identified all the assets acquired and all the liabilities assumed, and followed ASC 805-20’s measurement procedures for recognition of the fair value of net assets acquired.
The excess of the purchase price over the aggregate
fair value of assets acquired was allocated to goodwill which amounted to US$
The management performed an evaluation on the impairment
of goodwill, and due to the lower-than-expected revenue and profit and unfavorable business environment, the management recorded an impairment
loss on goodwill of Biowin, which amounted to US$
The identifiable goodwill acquired and the carrying value consisted of the following:
| March 31, 2025 | June 30, 2024 | |||||||
| Goodwill | $ | $ | ||||||
| Less: impairment for goodwill | ( | ) | ( | ) | ||||
| Goodwill, net | ||||||||
| Less: goodwill, net held for discontinued operations | ||||||||
| Goodwill, net held for continuing operations | $ | $ | ||||||
| 27 |
The following table summarizes the allocation of estimated fair values of net assets acquired and liabilities assumed:
| Accounts receivable, net | $ | |||
| Inventories, net | ||||
| Other current assets, net | ||||
| Property and equipment, net | ||||
| Intangible assets | ||||
| Operating lease right-of-use assets | ||||
| Goodwill | ||||
| Deferred tax assets, net | ||||
| Short-term bank loans | ( | ) | ||
| Accounts payable | ( | ) | ||
| Advances from customers | ( | ) | ||
| Other current liabilities | ( | ) | ||
| Operating lease liabilities - non-current | ( | ) | ||
| Deferred tax liabilities | ( | ) | ||
| Non-controlling interest | ( | ) | ||
| Total purchase price for acquisition, net of US$ | $ |
The fair value of identified intangible assets, which are trademarks and patents, and its estimated useful lives as of March 31, 2025 is as follows:
| Average | ||||||
| Useful Life | ||||||
| (in Years) | ||||||
| Intangible assets | $ | |||||
| Less: accumulated amortization | ( | ) | ||||
| Total intangible assets, net | ||||||
| Less: intangible assets, net held for discontinued operation | ||||||
| Intangible assets, net held for continuing operations | $ | |||||
The amortization expense of intangible assets was
US$
Under ASC 805-10, acquisition-related costs (i.e., advisory, legal, valuation and other professional fees) are not included as a component of consideration transferred, but are expensed in the periods in which the costs are incurred. Acquisition-related costs were for the nine and three months ended March 31, 2025 and 2024.
The Company has included the operating results of
Biowin in continuing operations in its unaudited condensed consolidated financial statements since the Acquisition Date. US$
| 28 |
Acquisition of Wintus
On May 29, 2023, Shineco Life entered into a stock
purchase agreement with Dream Partner, Wintus and the Wintus Sellers, pursuant to which Shineco Life shall acquire
The transaction was accounted for in accordance with the provisions of ASC 805-10, Business Combinations. The Company retained independent appraisers to advise management in the determination of the fair value of the various assets acquired and liabilities assumed. The values assigned in these financial statements represent management’s best estimate of fair values as of the Acquisition Date.
As required by ASC 805-20, Business Combinations—Identifiable Assets and Liabilities, and Any Non-controlling Interest, management conducted a review to reassess whether they identified all the assets acquired and all the liabilities assumed, and followed ASC 805-20’s measurement procedures for recognition of the fair value of net assets acquired.
The excess of the purchase price over the aggregate
fair value of assets acquired was allocated to goodwill, which amounted to US$
The management performed an evaluation on the impairment
of goodwill, and due to the lower-than-expected revenue and profit and unfavorable business environment, our management recorded an impairment
loss on the goodwill of Wintus, which amounted to US$
The identifiable goodwill acquired and the carrying value consisted of the following:
| March 31, 2025 | June 30, 2024 | |||||||
| Goodwill | $ | $ | ||||||
| Less: impairment for goodwill | ( | ) | ( | ) | ||||
| Goodwill, net | ||||||||
| Less: goodwill, net held for discontinued operations | ( | ) | ( | ) | ||||
| Goodwill, net held for continuing operations | $ | $ | ||||||
| 29 |
The following table summarizes the allocation of estimated fair values of net assets acquired and liabilities assumed:
| Accounts receivable, net | $ | |||
| Advances to suppliers, net | ||||
| Inventories, net | ||||
| Derivative financial assets | ||||
| Other current assets, net | ||||
| Property and equipment, net | ||||
| Intangible assets | ||||
| Operating lease right-of-use assets | ||||
| Goodwill | ||||
| Short-term bank loans | ( | ) | ||
| Accounts payable | ( | ) | ||
| Advances from customers | ( | ) | ||
| Tax payable | ( | ) | ||
| Deferred income | ( | ) | ||
| Other current liabilities | ( | ) | ||
| Long-term bank loans | ( | ) | ||
| Operating lease liabilities - non-current | ( | ) | ||
| Deferred tax liabilities | ( | ) | ||
| Non-controlling interest | ( | ) | ||
| Total purchase price for acquisition, net of US$ | $ |
The fair value of identified intangible assets, which are trademarks and patents, and its estimated useful lives as of March 31, 2025 is as follows:
| Average | ||||||||
| Useful Life | ||||||||
| (in Years) | ||||||||
| Intangible assets | $ | |||||||
| Less: accumulated amortization | ( | ) | ||||||
| Total intangible assets, net | ||||||||
| Less: intangible assets, net held for discontinued operation | ( | ) | ||||||
| Intangible assets, net held for continuing operations | $ | |||||||
The amortization expense of intangible assets was
US$
Under ASC 805-10, acquisition-related costs (i.e.,
advisory, legal, valuation and other professional fees) are not included as a component of consideration transferred, but are expensed
in the periods in which the costs are incurred. Acquisition-related costs were and US$
| 30 |
The Company has included the operating results of
Wintus in discontinued operations in its unaudited condensed consolidated financial statements since the Acquisition Date. US$
NOTE 12 - RELATED PARTY TRANSACTIONS
Due from Related Parties, Net
The Company has made temporary advances to certain stockholders and senior management of the Company and to other entities that are either owned by family members of those stockholders or to other entities that the Company has investments in. The receivable are non-interest bearing and due on demand.
As of March 31, 2025 and June 30, 2024, the outstanding amounts due from related parties consisted of the following:
| March 31, 2025 | June 30, 2024 | |||||||
| Chongqing Yufan Trading Co., Ltd (“Chongqing Yufan”) | $ | $ | ||||||
| Chongqing Dream Trading Co., Ltd | ||||||||
| Wintus China Limited | ||||||||
| Fujian Xinglinchun Health Industry Co., Ltd | ||||||||
| Subtotal | ||||||||
| Less: allowance for credit losses | ( | ) | ( | ) | ||||
| Total due from related parties, net | ||||||||
| Less: due from related parties, held for discontinued operations | ( | ) | ( | ) | ||||
| Due from related parties, held for continuing operations | $ | $ | ||||||
Due to Related Parties
As of March 31, 2025 and June 30, 2024, the Company
had related party payables of US$
| 31 |
As of March 31, 2025 and June 30, 2024, the outstanding amounts due to related parties consisted of the following:
| March 31, 2025 | June 30, 2024 | |||||||
| Wang Sai | $ | $ | ||||||
| Huang Shanchun | ||||||||
| Liu Fengming | ||||||||
| Yan Lixia | ||||||||
| Zhan Jiarui | ||||||||
| Liu Xiqiao | ||||||||
| Lyu Jiajia (a) | ||||||||
| Zhao Pengfei | ||||||||
| Wang Xiaohui(b) | ||||||||
| Chi Keung Yan(b) | ||||||||
| Fuzhou Meidashan Biotechnology Co., Ltd. | ||||||||
| Chongqing Fuling District Renyi Zhilu Silk Industry Co., Ltd | ||||||||
| Chongqing Huajian Housing Development Co., Ltd (“Chongqing Huajian”) | ||||||||
| Total due to related parties | ||||||||
| Less: due to related parties, held for discontinued operations | ( | ) | ( | ) | ||||
| Due to related parties, held for continuing operations | $ | $ | ||||||
| a. | |
| b. |
Interest expenses on loans due to related parties
were US$
Interest expenses on loans due to related parties were and US$ from discontinued operations for the nine months ended March 31, 2025 and 2024, respectively. Interest expenses on loans due to related parties were both from discontinued operations for the three months ended March 31, 2025 and 2024.
Sales to a Related Party
The Company’s discontinued operation, Wintus,
made sales of US$
Loan guarantee provided by related parties
The Company’s related parties provide a guarantee for the Company’s bank loans (see Note 13).
| 32 |
Loan guarantee provided to a related party
As of March 31, 2025 and June 30, 2024, Chongqing
Wintus (New Star) Enterprises Group (“Chongqing Wintus”) provided a guarantee that amounted to US$
Lease from a related party
The Company entered into a two-year lease agreement for the lease of office space from a related party company, of which the CEO is the Company’s shareholder.
As of March 31, 2025, the operating lease right-of-use
assets and corresponding operating lease liabilities of leases from the related party held for continuing operation were US$
As of June 30, 2024, the operating lease right-of-use
assets and corresponding operating lease liabilities of leases from the related party held for continuing operation were US$
During the nine months ended March 31, 2025 and 2024,
the Company’s continuing operations incurred operating lease expenses in leases from the related party of US$
NOTE 13 – LOANS
Short-term loans
Short-term loans from third parties
During the year ended June 30, 2024, the Company entered
into loan agreements with two third parties. These short-term loans from third parties are mainly used for short-term funding to support
the Company’s working capital needs. One of the loans amounting to US$
The Company recorded interest expenses from continuing
operations of US$
| 33 |
Short-term bank loans
Short-term bank loans consisted of the following:
| Lender | March 31, 2025 | Maturity Date | Int. Rate/Year | |||||||
| Jiangnan Rural Commercial Bank(a) | $ | % | ||||||||
| Bank of Jiangsu(b) | % | |||||||||
| Bank of China(c) | % | |||||||||
| United Overseas Bank(d) | % | |||||||||
| Industrial and Commercial Bank of China | % | |||||||||
| Bank of China(e) | % | |||||||||
| Chongqing Rural Commercial Bank(f) | % | |||||||||
| Industrial and Commercial Bank of China(g) | % | |||||||||
| Total short-term bank loans | ||||||||||
| Less: short-term bank loans, held for discontinued operations | ( | ) | ||||||||
| Short-term bank loans, held for continuing operations | $ | |||||||||
The loans outstanding were guaranteed by the following properties, entities or individuals:
| a. | |
| b. | |
| c. | |
| d. | |
| e. | |
| f. | |
| g. |
| 34 |
| Lender | June 30, 2024 | Maturity Date | Int. Rate/Year | |||||||
| Jiangnan Rural Commercial Bank(a) | $ | % | ||||||||
| Bank of Jiangsu(b) | % | |||||||||
| Bank of China(c) | % | |||||||||
| United Overseas Bank(d) | % | |||||||||
| Industrial and Commercial Bank of China | % | |||||||||
| Industrial and Commercial Bank of China(e) | % | |||||||||
| Bank of China(f) | % | |||||||||
| Chongqing Rural Commercial Bank(g) | % | |||||||||
| Total short-term bank loans | ||||||||||
| Less: short-term bank loans, held for discontinued operations | ( | ) | ||||||||
| Short-term bank loans, held for continuing operations | $ | |||||||||
The loans outstanding were guaranteed by the following properties, entities or individuals:
| a. | |
| b. | |
| c. | |
| d. | |
| e. | |
| f. | |
| g. |
| 35 |
Long-term loans
Long-term bank loans consisted of the following:
| Lender | March 31, 2025 | Maturity Date | Int. Rate/Year | |||||||
| Chongqing Rural Commercial Bank(a) | $ | % | ||||||||
| Bank of Chongqing(b) | % | |||||||||
| Total long-term bank loans | ||||||||||
| Less: long-term bank loans, held for discontinued operations | ( | ) | ||||||||
| Long-term bank loans, held for continuing operations | $ | |||||||||
| Long-term bank loans-current, held for discontinued operations | $ | |||||||||
| Long-term bank loans-non-current, held for discontinued operations | $ | |||||||||
The loans outstanding were guaranteed by the following properties, entities or individuals:
| a. | |
| b. |
| Lender | June 30, 2024 | Maturity Date | Int. Rate/Year | |||||||
| Chongqing Rural Commercial Bank(a) | $ | % | ||||||||
| Bank of Chongqing(b) | % | |||||||||
| Total long-term bank loans | ||||||||||
| Less: long-term bank loans, held for discontinued operations | ( | ) | ||||||||
| Long-term bank loans, held for continuing operations | $ | |||||||||
| Long-term bank loans-current, held for discontinued operations | $ | |||||||||
| Long-term bank loans-non-current, held for discontinued operations | $ | |||||||||
The loans outstanding were guaranteed by the following properties, entities or individuals:
| a. | |
| b. |
| 36 |
The Company recorded interest expenses from continuing
operations of US$
The annual weighted average interest rates from continuing
operations were
The Company recorded interest expenses from discontinued
operations of US$
The annual weighted average interest rates from discontinued
operations were
NOTE 14 - CONVERTIBLE NOTES PAYABLE
On June 16, 2021, the Company entered into a Securities
Purchase Agreement pursuant to which the Company issued an unsecured convertible promissory note with a maturity date of June 17, 2022
(“the Note”) to an institutional accredited investor Streeterville Capital, LLC (“Investor”). The Note has the
original principal amount of US$
On July 16, 2021, the Company entered into a Securities
Purchase Agreement (the “July Agreement”) pursuant to which the Company issued two unsecured convertible promissory notes
with a one-year maturity term (the “Notes”) to the same Investor. The first convertible promissory note (“Note #1”)
has an original principal amount of US$
| 37 |
On August 19, 2021, the Company entered into a Securities
Purchase Agreement (the “Agreement”) pursuant to which the Company issued an unsecured convertible promissory note with a
maturity date of August 23, 2022 (the “Note”) to the same Investor. The Note has an original principal amount of US$
For the above-mentioned convertible promissory notes
issued, interest accrues on the outstanding balance of these notes at
For the nine months ended March 31, 2025 and 2024,
a total of US$
As of March 31, 2025, shares of the Company’s
common stock totaling were issued by the Company to the Investor equaling principal and interests amounted to US$
NOTE 15 - TAXES
(a) Corporate Income Taxes
The Company is subject to income taxes on an entity basis on income arising in or derived from the location in which each entity is domiciled.
| 38 |
Shineco is incorporated in the United States and has
no operating activities. Shineco Life is incorporated in Hong Kong and is subject to profit taxes in Hong Kong at a rate of
On December 22, 2017, The Act was enacted. The Act
imposes a one-time transition tax on deemed repatriation of historical earnings of foreign subsidiaries, and future foreign earnings are
subject to U.S. taxation. The change in rate has caused the Company to re-measure its income tax liability and record an estimated income
tax expense of US$
i) The components of the income tax provision (benefit) were as follows:
For the nine months ended March 31, | For the three months ended March 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Current income tax provision (benefit) | $ | $ | $ | ( | ) | $ | ||||||||||
| Deferred income tax provision (benefit) | ( | ) | ( | ) | ( | ) | ||||||||||
| Total income tax provision (benefit) | ( | ) | ( | ) | ( | ) | ||||||||||
| Less: income tax provision (benefit), held for discontinued operations | ( | ) | ||||||||||||||
| Income tax benefit, held for continuing operations | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
ii) The components of the deferred tax liability were as follows:
| March 31, 2025 | June 30, 2024 | |||||||
| Deferred tax assets: | ||||||||
| Allowance for credit loss/doubtful accounts | $ | $ | ||||||
| Inventory reserve | ||||||||
| Net operating loss carry-forwards | ||||||||
| Total | ||||||||
| Valuation allowance | ( | ) | ( | ) | ||||
| Total deferred tax assets | ||||||||
| Deferred tax liability: | ||||||||
| Intangible assets | ( | ) | ( | ) | ||||
| Total deferred tax liability | ( | ) | ( | ) | ||||
| Deferred tax liability, net | ( | ) | ( | ) | ||||
| Less: deferred tax liability, net, held for discontinued operations | ( | ) | ( | ) | ||||
| Deferred tax liability, net, held for continuing operations | $ | ( | ) | $ | ( | ) | ||
| 39 |
| March 31, 2025 | June 30, 2024 | |||||||
| Beginning balance | $ | $ | ||||||
| Acquisition of subsidiaries | ||||||||
| Disposal of Tenet Jove | ( | ) | ||||||
| Current year addition | ||||||||
| Exchange difference | ( | ) | ||||||
| Valuation allowance | ||||||||
| Less: valuation allowance, held for discontinued operations | ( | ) | ( | ) | ||||
| Valuation allowance, held for continuing operations | $ | $ | ||||||
(b) Value-Added Tax
The Company is subject to a VAT for selling goods.
In the event that the PRC tax authorities dispute the date on which revenue is recognized for tax purposes, the PRC tax office has the right to assess a penalty based on the amount of the taxes which are determined to be late or deficient, and the penalty will be expensed in the period if and when a determination is made by the tax authorities. There were no assessed penalties during the nine and three months ended March 31, 2025 and 2024, respectively.
(c) Taxes Payable
Taxes payable consisted of the following:
| March 31, 2025 | June 30, 2024 | |||||||
| Income tax payable | $ | $ | ||||||
| Value added tax payable | ||||||||
| Business tax and other taxes payable | ||||||||
| Total tax payable | ||||||||
| Less: tax payable, held for discontinued operations | ( | ) | ( | ) | ||||
| Tax payable, held for continuing operations | $ | $ | ||||||
| Income tax payable - current portion | $ | $ | ||||||
| Less: income tax payable - current portion, held for discontinued operations | ( | ) | ( | ) | ||||
| Income tax payable - current portion, held for continuing operations | $ | $ | ||||||
| Income tax payable - noncurrent portion | $ | $ | ||||||
| Less: income tax payable - noncurrent portion, held for discontinued operations | ||||||||
| Income tax payable - noncurrent portion, held for continuing operations | $ | $ | ||||||
| 40 |
NOTE 16 - STOCKHOLDERS’ EQUITY
Initial Public Offering
On September 28, 2016, the Company completed its initial
public offering of shares of common stock (before the effect of the reverse stock splits mentioned below) at a price of US$
per share for gross proceeds of US$
Statutory Reserve
The Company is required to make appropriations to reserve funds, comprising the statutory surplus reserve and discretionary surplus reserve, based on after-tax net income determined in accordance with generally accepted accounting principles of the PRC (“PRC GAAP”).
Appropriations to the statutory surplus reserve are
required to be at least
On July 10, 2020, the Company’s stockholders
approved a
On April 10, 2021, the Company issued shares
of common stock to selected investors at a price of US$ per share. The Company received net proceeds of US$
On August 30, 2023, the Board of Directors of the
Company approved the issuance of shares of common stock pursuant to the Company’s 2023 Equity Incentive Plan (the “2023 Plan”)
in the aggregate amount of shares (the “Shares”) to its non-officer employees. The fair value of the Shares was US$
On May 29, 2023, Shineco Life entered into a stock
purchase agreement with Dream Partner, Wintus and the Wintus Sellers, pursuant to which Shineco Life shall acquire
On December 22, 2023, the Company entered into a securities
purchase agreement (the “Purchase Agreement”) with certain non-US investors (the “Investors”). Under the Purchase
Agreement, the Company agreed to sell to the Investors up to shares (the “Shares”) of its common stock at a per share
purchase price of US$ for gross proceeds of up to US$
| 41 |
On February 1, 2024, the Company’s stockholders
approved a
On June 18, 2024, the Board of Directors of
the Company approved the issuance of shares of common stock pursuant to the Company’s 2024 Equity Incentive Plan (the “2024
Plan”) in the aggregate amount of shares (the “Shares”) to its non-officer employees. The fair value of the Shares
was US$
On June 20, 2024, the Company entered into a securities
purchase agreement with certain non-U.S. investors (the “June 2024 Purchasers”), pursuant to which the Company agreed to sell,
and the Purchasers agreed to purchase, severally and not jointly, an aggregate of shares of common stock of the Company (the “June
2024 Shares”) at an offering price of US$ per share for gross proceeds of up to US$
On July 11, 2024, the Company entered into an Underwriting
Agreement with EF Hutton LLC, as the representative for several underwriters, relating to the underwritten public offering (the “Offering”)
of shares of common stock at a public offering price of US$ per share, for aggregate gross proceeds of approximately US$
On August 22, 2024, the Company entered into a securities
purchase agreement (the “SPA”) with 22 purchasers, each an unrelated third party to the Company (collectively, the “August
2024 Purchasers”). Pursuant to the SPA, the August 2024 Purchasers agree to purchase, and the Company agreed to issue and sell to
the August 2024 Purchasers, an aggregate of shares of the Company’s common stock, par value US$ per share (the “August
2024 Shares”), at a purchase price of US$ per share, and for an aggregate purchase price of US$
| 42 |
On October 21, 2024, the Company’s stockholders
approved a
On December 24, 2024, the Company entered into a
securities purchase agreement with nine non-U.S. investors (the “Purchasers”), pursuant to which the Company agreed to
sell, and the December 2024 Purchasers agreed to purchase, severally and not jointly, an aggregate of
shares of common stock of the Company (the “Shares”) at a purchase price of US$
per share for gross proceeds of US$
NOTE 17 - CONCENTRATIONS AND RISKS
The Company maintains principally all bank accounts
in the PRC. The cash balance held in the PRC bank accounts from the continuing operations was US$
During the nine and three months ended March 31, 2025
and 2024, almost
For the nine months ended March 31, 2025, two customers
accounted for approximately
For the nine months ended March 31, 2025, no customer
accounted for more than
For the nine months ended March 31, 2024, three customers
accounted for approximately
For the nine months ended March 31, 2024, four customers
accounted for approximately
As of March 31, 2025, one customer accounted for approximately % of the Company’s accounts receivable from the continuing operations. As of March 31, 2025, three customers accounted for approximately % of the Company’s accounts receivable from the discontinued operations.
As of June 30, 2024, one customer accounted for approximately % of the Company’s accounts receivable from the continuing operations. As of June 30, 2024, two customers accounted for approximately % of the Company’s accounts receivable from the discontinued operations.
| 43 |
For the nine months ended March 31, 2025, one vendor accounted for approximately % of the Company’s total purchases from the continuing operations. For the three months ended March 31, 2025, no vendor accounted for more than % of the Company’s total purchases from the continuing operations.
For the nine months ended March 31, 2025, two vendors accounted for approximately % of the Company’s total purchases from the discontinued operations. For the three months ended March 31, 2025, four vendors accounted for approximately % of the Company’s total purchases from the discontinued operations.
For the nine months ended March 31, 2024, two vendors accounted for approximately % of the Company’s total purchases from the continuing operations. For the three months ended March 31, 2024, four vendors accounted for approximately % of the Company’s total purchases from the continuing operations.
For the nine months ended March 31, 2024, two vendors accounted for approximately % of the Company’s total purchases from the discontinued operations. For the three months ended March 31, 2024, one vendor accounted for approximately % of the Company’s total purchases from the discontinued operations.
NOTE 18 - COMMITMENTS AND CONTINGENCIES
Lease commitments
The Company leases offices for operation under operating
leases. Future minimum lease payments of US$
Legal Contingencies
On November 26, 2021, the Company filed a complaint
in the Supreme Court of the State of New York, New York County against Lei Zhang and Yan Li, as defendants, and Transhare Corporation
(“Transhare”), as a nominal defendant, asserting that defendants had not paid for certain restricted shares of the Company’s
common stock pursuant to stock purchase agreements they executed with the Company. In December, defendants filed an answer and counterclaim
against the Company, which they amended on January 27, 2022 after the Company moved to dismiss their counterclaims. They brought claims
for, among others, breach of contract, breach of the covenant of good faith and fair dealing, and fraud, asserting that the Company made
false and materially misleading statements, specifically regarding the sale of such shares to Lei Zhang and Yan Li and the removal of
their restrictive legends. Defendants are seeking money damages of at least US$
Nominal defendant Transhare Corporation moved to dismiss the defendants’ counterclaim against it for wrongful refusal to remove restrictions pursuant to 6 Del. C. § 8-401, and its motion was fully submitted in April 2022. On September 9, 2022, the Court granted Transhare Corporation’s motion to dismiss defendants’ counterclaim for wrongful refusal to remove restrictions. Defendants have appealed the Court’s September 9, 2022 order dismissing defendants’ counterclaim for wrongful refusal to remove restrictions. On October 3, 2022, the parties submitted a stipulation dismissing defendants’ outstanding counterclaim against Transhare Corporation seeking declaratory judgment.
The Company participated in a formal mediation with
the defendants Lei Zhang and Yan Li on September 18, 2023. As a result of the mediation, the parties were able to reach a settlement agreement
in December 2023. The parties executed a Settlement Agreement on December 21, 2023, and the claims by each side were formally dismissed
by the court on December 22, 2023. The subscription receivable amounted to US$
| 44 |
Introduced
by a business partner (the “Party A”) of Life Science, Life Science entered into a loan agreement with an individual
(the “the Plaintiff”) on April 15, 2024 (the Party A, Life Science and the Plaintiff are collectively called the
“Three Parties”). Pursuant to the loan agreement, Life Science would obtain a loan in the amount of RMB
On
November 8, 2024, Zhejiang Shijin Packaging Co., Ltd. (“the Plaintiff”) submitted a civil complaint to the
People’s Court of Deqing County, Zhejiang Province (the “Court”) against the Company’s subsidiary Biowin.
The complaint requested that Biowin make the compensation to the Plaintiff for the outstanding trade payable plus interests
and the litigation fee in this case shall be borne by Biowin. On December 5, 2024, the Court issued a judgement that Biowin shall
pay the Plaintiff the outstanding trade payable, the litigation fee, and the interest expense if payments are not made according to
the schedule. As of March 31, 2025, Biowin recorded RMB
On
April 16, 2025, Bank of Jiangsu (“the Plaintiff”) commenced a lawsuit against the Company’s subsidiary, Biowin,
in the Jiangsu Changzhou High-Tech Industrial Development Zone People’s Court. The Plaintiff alleged that Biowin entered into a
loan agreement with the Plaintiff on June 27, 2024, pursuant to which Biowin obtained
a loan in the amount of RMB
NOTE 19 - SEGMENT REPORTING
ASC 280, “Segment Reporting,” establishes standards for reporting information about operating segments on a basis consistent with the Group’s internal organizational management structure as well as information about geographical areas, business segments, and major customers in for details on the Group’s business segments.
The Company’s chief operating decision maker has been identified as the Chief Executive Officer who reviews the financial information of separate operating segments when making decisions about allocating resources and assessing performance of the Group. Based on management’s assessment, the Company has determined that it has following operating segments according to its major products and locations as follows:
| ● | Developing, manufacturing, and distributing of specialized fabrics, textile products, and other by-products derived from an indigenous Chinese plant called Apocynum Venetum, commonly known as “Bluish Dogbane” or known in Chinese as “Luobuma” (referred to herein as Luobuma), which are reclassified as discontinued operations: |
| The operating companies of this segment, namely Tenet-Jove and Tenet Huatai, specialize in Luobuma growing, development and manufacturing of relevant products, as well as purchasing Luobuma raw materials processing. | |
| This segment’s operations are focused in the north region of Mainland China, mostly carried out in Beijing, Tianjin, and Xinjiang. | |
| ● | Planting, processing, and distributing of green and organic agricultural produce as well as growing and cultivating of Chinese Yew trees (“Other agricultural products”), which are reclassified as discontinued operations: |
| The operating company of this segment, Qingdao Zhihesheng, is engaged in the business of growing and distributing green and organic vegetables and fruits. This segment has been focusing its efforts on the growing and cultivating of Chinese yew trees (formally known as “taxus media”), a small evergreen tree whose branches can be used for the production of medications believed to be anti-cancer and the tree itself can be used as an ornamental indoor bonsai tree, which are known to have the effect of purifying air quality. The operations of Zhihesheng are located in the East and North regions of Mainland China, mostly carried out in Shandong Province and in Beijing, where Zhihesheng have newly developed over 100 acres of modern greenhouses for cultivating yew trees and other plants. |
| 45 |
| The other operating company of this segment, Guangyuan, is engaged in the business of landscaping, afforestation, road greening, scenic greening, garden engineering, landscaping construction, and green afforestation, especially in planting fast-growing bamboo willows and scenic greening trees. The operations of Guangyuan are located in the North regions of Mainland China, mostly carried out in Shanxi Province, where Guangyuan has developed over 350 acres of farmland for cultivating bamboo willows and other plants. | |
| ● | Providing domestic air and overland freight forwarding services (“Freight services”), which are reclassified as discontinued operations: |
| The operating company of this segment, Zhisheng Freight, is engaged in the business of providing domestic air and overland freight forwarding services by outsourcing these services to a third party. The Company merely serves as an agent and its obligation is to facilitate third-party logistic companies in fulfilling its performance obligation for specified freight services. |
| ● | Developing, producing and distributing innovative rapid diagnostic products and related medical devices for the most common diseases (“Rapid diagnostic and other products”): |
| The operating company of this segment, Biowin, specializes in the development, production and distribution of innovative rapid diagnostic products and related medical devices for the most common diseases. The operations of this segment are located in Jiangsu Province. Its products are sold not only in China but also overseas in countries such as Germany, Spain, Italy, Thailand, Japan and others. | |
| ● | Producing, processing and distribution of agricultural products, such as silk and silk fabrics, as well as trading of fresh fruit (“Other agricultural products”), which are reclassified as discontinued operations: |
| The operating company of this segment, Wintus, specializes in producing, processing and distributing agricultural products, such as silk and silk fabrics, as well as fresh fruit. The operations of this segment are located in Chongqing, China. Wintus has established approximately 150,000 acres of mulberry orchards in Fuling District and Wulong District of Chongqing. Wintus operates a silk factory in Liangping District, Chongqing that processes silk products, which are then distributed worldwide through dealers. Its products are sold not only in China but also overseas countries such as the United States, Europe (Germany, France, Italy, Poland), Japan, South Korea, and Southeast Asia (India, Thailand, Indonesia, Bangladesh, and Cambodia), among other countries and regions. In addition to silk products, Wintus also engages in the fruit trading business. It imports fruits from Southeast Asia and other regions, distributing them through dealers to supermarkets and stores nationwide in China. | |
| ● | Developing and selling healthy meals for people with slow metabolic health and those in recovery from metabolic disorders (“Healthy meals products”): |
| The operating company of this segment, Fuzhou Meida, operates a health-oriented chain restaurant that focuses on the concept of “improving metabolism through diet.” Fuzhou Meida specializes in developing healthy meals for people with slow metabolic health and those in recovery from metabolic disorders. Fuzhou Meida recently opened its restaurant in Fuzhou City, Fujian Province. The restaurant features an open kitchen and adopts a modern Chinese style, offering a variety of modern Chinese healthy light meals and metabolism-boosting meal sets. The Company plans to gradually establish additional branches in key cities across China, including Beijing, Shanghai, Guangzhou, and other southeastern coastal regions. |
| 46 |
The following table presents summarized information by segment for the nine months ended March 31, 2025:
| For the nine months ended March 31, 2025 | ||||||||||||||||||||
| Continuing Operations | Discontinued Operations | |||||||||||||||||||
| Rapid diagnostic and other | Healthy meals | Other agricultural | Luobuma | |||||||||||||||||
| products | products | products | products | Total | ||||||||||||||||
| Segment revenue | $ | $ | $ | $ | $ | |||||||||||||||
| Cost of revenue and related business and sales tax | ||||||||||||||||||||
| Gross profit | ||||||||||||||||||||
| Gross profit % | % | % | % | % | ||||||||||||||||
The following table presents summarized information by segment for the nine months ended March 31, 2024:
| For the nine months ended March 31, 2024 | ||||||||||||||||||||
| Continuing Operations | Discontinued Operations | |||||||||||||||||||
| Rapid diagnostic and other | Healthy meals | Other agricultural | Luobuma | |||||||||||||||||
| products | products | products | products | Total | ||||||||||||||||
| Segment revenue | $ | $ | $ | $ | $ | |||||||||||||||
| Cost of revenue and related business and sales tax | ||||||||||||||||||||
| Gross profit (loss) | ( | ) | ||||||||||||||||||
| Gross profit (loss) % | % | ( | )% | % | % | % | ||||||||||||||
The following table presents summarized information by segment for the three months ended March 31, 2025:
| For the three months ended March 31, 2025 | ||||||||||||||||||||
| Continuing Operations | Discontinued Operations | |||||||||||||||||||
| Rapid diagnostic and other | Healthy meals | Other agricultural | Luobuma | |||||||||||||||||
| products | products | products | products | Total | ||||||||||||||||
| Segment revenue | $ | $ | $ | $ | $ | |||||||||||||||
| Cost of revenue and related business and sales tax | ||||||||||||||||||||
| Gross profit (loss) | ( | ) | ||||||||||||||||||
| Gross profit (loss) % | ( | )% | % | - | % | |||||||||||||||
| 47 |
The following table presents summarized information by segment for the three months ended March 31, 2024:
| For the three months ended March 31, 2024 | ||||||||||||||||||||
| Continuing Operations | Discontinued Operations | |||||||||||||||||||
| Rapid diagnostic and other | Healthy meals | Other agricultural | Luobuma | |||||||||||||||||
| products | products | products | products | Total | ||||||||||||||||
| Segment revenue | $ | $ | $ | $ | $ | |||||||||||||||
| Cost of revenue and related business and sales tax | ||||||||||||||||||||
| Gross profit (loss) | ( | ) | ||||||||||||||||||
| Gross profit (loss) % | % | ( | )% | % | - | % | ||||||||||||||
Total assets as of March 31, 2025 and June 30, 2024 were as follows:
| March 31, 2025 | June 30, 2024 | |||||||
| Other agricultural products | $ | $ | ||||||
| Rapid diagnostic and other products | ||||||||
| Healthy meals products | ||||||||
| Total assets | ||||||||
| Less: total assets held for discontinued operations | ( | ) | ( | ) | ||||
| Total assets, held for continuing operations | $ | $ | ||||||
NOTE 20 - DISCONTINUED OPERATIONS
On May 29, 2023, Shineco Life entered into a stock
purchase agreement with Dream Partner Limited, a BVI corporation (“Dream Partner”), Chongqing Wintus Group, a corporation
incorporated under the laws of mainland China (“Wintus”), and certain shareholders of Dream Partner (the “Wintus Sellers”),
pursuant to which Shineco Life shall acquire
On March 20, 2025, Shineco Life entered into a stock
purchase agreement (the “SPA”) with Yi Yang (the “Seller”), a current and only shareholder of FuWang (HK) International
Company Limited (“FuWang (HK)”), a company limited by shares incorporated in Hong Kong. Pursuant to the SPA, the Seller sold
| 48 |
In accordance with ASU No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, a disposal of a component of an entity or a group of components of an entity is required to be reported as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results when the components of an entity meets the criteria in paragraph 205-20-45-1E to be classified as held for sale. When all of the criteria to be classified as held for sale are met, including management, having the authority to approve the action, commits to a plan to sell the entity, the major current assets, other assets, current liabilities, and non-current liabilities shall be reported as components of total assets and liabilities separate from those balances of the continuing operations. At the same time, the results of all discontinued operations, less applicable income taxes benefit, shall be reported as a component of net loss separate from the net loss of continuing operations in accordance with ASC 205-20-45. The assets and liabilities of the Tenet-Jove Disposal Group and Wintus have been reclassified as “assets of discontinued operations” and “liabilities of discontinued operations” within current and non-current assets and liabilities, respectively, on the unaudited condensed consolidated balance sheet as of March 31, 2025 and the consolidated balance sheet as of June 30, 2024. The results of operations of Tenet-Jove Disposal Group and Wintus have been reclassified to “net income (loss) from discontinued operations” in the unaudited condensed consolidated statements of loss and comprehensive loss for the nine and three months ended March 31, 2025 and 2024.
The carrying amount of the major classes of assets and liabilities of discontinued operations as of March 31, 2025 and June 30, 2024 consist of the following:
| March 31, 2025 | June 30, 2024 | |||||||
| Assets of discontinued operation: | ||||||||
| Current assets: | ||||||||
| Cash | $ | $ | ||||||
| Restricted cash | ||||||||
| Accounts receivables, net | ||||||||
| Due from related parties | ||||||||
| Inventories, net | ||||||||
| Advances to suppliers, net | ||||||||
| Derivative financial assets | ||||||||
| Other current assets, net | ||||||||
| Total current assets of discontinued operation | ||||||||
| Property and equipment, net | ||||||||
| Land use right, net of accumulated amortization | ||||||||
| Intangible assets, net | ||||||||
| Goodwill | ||||||||
| Operating lease right-of-use assets | ||||||||
| Total assets of discontinued operation | $ | $ | ||||||
| Liabilities of discontinued operation: | ||||||||
| Current liabilities: | ||||||||
| Short-term loans | $ | $ | ||||||
| Long-term loans - current portion | ||||||||
| Accounts payable | ||||||||
| Advances from customers | ||||||||
| Due to related parties | ||||||||
| Other payables and accrued expenses | ||||||||
| Deferred income | ||||||||
| Taxes payable | ||||||||
| Total current liabilities of discontinued operation | ||||||||
| Long-term loans - non-current | ||||||||
| Deferred tax liability | ||||||||
| Total liabilities of discontinued operation | $ | $ | ||||||
| 49 |
The summarized operating result of discontinued operations included in the Company’s unaudited condensed consolidated statements of loss and comprehensive loss consist of the following:
For the Nine Months Ended March 31, | For the Three Months Ended March 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| REVENUE | $ | $ | $ | $ | ||||||||||||
| COST OF REVENUE | ||||||||||||||||
| Cost of products | ||||||||||||||||
| Business and sales related tax | ||||||||||||||||
| Total cost of revenue | ||||||||||||||||
| GROSS PROFIT | ||||||||||||||||
| OPERATING EXPENSES | ||||||||||||||||
| General and administrative expenses | ||||||||||||||||
| Selling expenses | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| LOSS FROM OPERATIONS | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| OTHER EXPENSE | ||||||||||||||||
| Impairment loss on goodwill | ( | ) | ( | ) | ||||||||||||
| Investment income (loss) from derivative financial assets | ( | ) | ||||||||||||||
| Other income (expenses), net | ( | ) | ( | ) | ||||||||||||
| Interest expenses, net | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Total other expenses | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| LOSS BEFORE BENEFIT FOR INCOME TAXES FROM DISCONTINUED OPERATIONS | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| PROVISION (BENEFIT) FOR INCOME TAXES FROM DISCONTINUED OPERATIONS | ( | ) | ( | ) | ( | ) | ||||||||||
| LOSS FROM DISCONTINUED OPERATIONS, NET OFF TAX | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| INCOME ON DISPOSAL OF DISCONTINUED OPERATIONS | ||||||||||||||||
| NET INCOME (LOSS) FROM DISCONTINUED OPERATIONS | ( | ) | ( | ) | ( | ) | ||||||||||
| Net loss attributable to non-controlling interest | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| NET INCOME (LOSS) FROM DISCONTINUED OPERATIONS ATTRIBUTABLE TO SHINECO, INC. | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | ||||||
NOTE 21 - SUBSEQUENT EVENTS
On April 22, 2025, Shineco Life entered into a share purchase agreement (the “SPA”) with Dr. Lim Kah Meng (the “Seller”), the sole shareholder of InfiniClone Limited, a company incorporated under the laws of Hong Kong (“InfiniClone”). Pursuant to the SPA, the Seller shall sell % of the equity interests in InfiniClone Limited that he holds (the “InfiniClone Shares”) to Shineco Life. In consideration of the sale of the InfiniClone Shares, Shineco Life shall pay the Seller US$ in cash, and the Company will issue and transfer shares of the Company’s common stock, par value $ per share to the Seller within 90 days after the execution of the SPA. The transaction contemplated thereby and the issuance of the Shares has been approved by the Company’s board of directors, and the acquisition is expected to be completed in May 2025.
These unaudited condensed consolidated financial statements were approved by management and available for issuance on May 15, 2025, and the Company has evaluated subsequent events through this date. No subsequent events required adjustments to or disclosure in these unaudited condensed consolidated financial statements.
| 50 |
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS
Forward-Looking Statements
This Quarterly Report on Form 10-Q (the “Quarterly Report”) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is subject to the safe harbor created by those sections. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws. Forward-looking statements involve risks and uncertainties, such as statements about our plans, objectives, expectations, assumptions or future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “should,” “will,” “could,” and similar expressions denoting uncertainty or an action that may, will or is expected to occur in the future. These statements involve estimates, assumptions, known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from any future results, performances or achievements expressed or implied by the forward-looking statements.
Examples of forward-looking statements include:
| ● | the timing of the development of future products; | |
| ● | projections of revenue, earnings, capital structure, and other financial items; | |
| ● | local, regional, national, and global price fluctuations of raw materials; | |
| ● | statements of our plans and objectives, including those that relate to our proposed expansions and the effect such expansions may have on our revenue; | |
| ● | statements regarding the capabilities of our business operations; | |
| ● | statements of expected future economic performance; | |
| ● | statements regarding competition in our market; and | |
| ● | assumptions underlying statements regarding us or our business. |
The ultimate correctness of these forward-looking statements depends upon a number of known and unknown risks and events. Many factors could cause our actual results to differ materially from those expressed or implied in our forward-looking statements. Consequently, you should not place undue reliance on these forward-looking statements.
The forward-looking statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Nonetheless, we reserve the right to make such updates from time to time by press release, periodic report, or other method of public disclosure without the need for specific reference to this Quarterly Report. No such update shall be deemed to indicate that other statements not addressed by such update is incorrect or create an obligation to provide any other updates.
The information included in this Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with our unaudited condensed consolidated financial statements and the notes included in this Quarterly Report, and the audited consolidated financial statements and notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our Annual Report. All monetary figures are presented in U.S. dollars, unless otherwise indicated.
| 51 |
General Overview
Shineco, Inc. is a holding company incorporated in Delaware. Prior to the following acquisition and the termination of the VIE structure, as a holding company with no material operations of our own, we conducted a substantial majority of our operations through the operating entities established in the People’s Republic of China, or the PRC, primarily the variable interest entities (the “VIEs”). We did not have any equity ownership of the VIEs, instead we received the economic benefits of the VIEs’ business operations through certain contractual arrangements. Our common stock that currently listed on the Nasdaq Capital Markets are shares of our Delaware holding company. The Chinese regulatory authorities could disallow our structure, which could result in a material change in our operations and the value of our securities could decline or become worthless.
On December 30, 2022, Shineco Life Science Group Hong Kong Co., Limited (“Shineco Life”), a company established under the laws of Hong Kong and a wholly owned subsidiary of the Company, closed the acquisition of 51% of the issued equity interests of Changzhou Biowin Pharmaceutical Co., Ltd. (“Biowin”), a company established under the laws of China, pursuant to the previously announced stock purchase agreement, dated as of October 21, 2022, among Beijing Kanghuayuan Medicine Information Consulting Co., Ltd., a company established under the laws of China (“Seller”), Biowin, the Company and Shineco Life. As the consideration for the acquisition, the Company paid to Seller US$9,000,000 in cash and the Company issued 13,583 shares of the Company’s common stock, par value US$0.001 per share, to the equity holders of Biowin or any persons designated by Biowin. According to a supplementary agreement, dated as of December 30, 2022, by and among Shineco Life, the Seller and Biowin, the Seller owned 51% of the issued equity interests of Biowin before January 1, 2023, and transferred the 51% of the issued equity interests of Biowin together with its controlling rights of production and operation of Biowin to Shineco Life on January 1, 2023.
On May 29, 2023, Shineco Life entered into a stock purchase agreement with Dream Partner Limited, a BVI corporation (“Dream Partner”), Chongqing Wintus Group, a corporation incorporated under the laws of mainland China (“Wintus”), and certain shareholders of Dream Partner (the “Sellers”), pursuant to which Shineco Life shall acquire 71.42% equity interest in Wintus (the “Acquisition”). On September 19, 2023, the Company closed the Acquisition. As the consideration for the Acquisition, the Company (a) paid the Sellers an aggregate cash consideration of US$2,000,000; (b) issued certain shareholders, as listed in the agreement, an aggregate of 41,667 shares of the Company’s restricted Common Stock; and (c) transferred and sold to the Sellers 100% of the Company’s equity interest in Beijing Tenet-Jove Technological Development Co., Ltd. (“Tenet-Jove Shares”). Following the closing of the Acquisition and the sale of the Tenet-Jove Shares, the Company divested its equity interest in its operating subsidiary Tenet-Jove (“Tenet-Jove Disposal Group”) and thereby terminated its VIE Structure.
On March 20, 2025, Shineco Life entered into a stock purchase agreement with Yi Yang (the “Seller”), a current and only shareholder of FuWang (HK) International Company Limited (“FuWang (HK)”), a company limited by shares incorporated in Hong Kong. Pursuant to the agreement, the Seller sold 75% of the equity interests in FuWang (HK) to Shineco Life (“FuWang Acquisition”). In consideration of the FuWang Acquisition, (a) Shineco Life paid the Seller RMB 63.89 million in cash, (b) the Company issued and transferred 3,400,000 shares of the Company’s common stock, par value $0.001 per share to the Seller, and (c) the Company transferred its 71.42% equity interests in Wintus to the Seller. The Company obtained the controlling rights of production and operation of FuWang (HK) on April 1, 2025.
We used our subsidiaries’ vertically and horizontally integrated production, distribution, and sales channels to provide health and well-being focused plant-based products. Through our subsidiary, Biowin, which specializes in the development, production and distribution of innovative rapid diagnostic products and related medical devices for the most common diseases, we also stepped into the Point-of-Care Testing industry. Meanwhile, our subsidiary, Fuzhou Meida, opened its restaurant, which is a health-oriented chain restaurant that focuses on the concept of “improving metabolism through diet.” As of March 31, 2025, the Company, through its subsidiaries, operates the following main business segments:
| 52 |
Developing, producing and distributing innovative rapid diagnostic products and related medical devices for the most common diseases (“Rapid diagnostic and other products”): - This segment is conducted through Biowin, which specializes in the development, production and distribution of innovative rapid diagnostic products and related medical devices for the most common diseases. The operations of this segment are located in Jiangsu Province. Its products are sold not only in China, but also overseas countries such as Germany, Spain, Italy, Thailand, Japan and other countries.
Developing and selling healthy meals for people with slow metabolic health and those in recovery from metabolic disorders (“Healthy meals products”): – This segment is conducted through Fuzhou Meida, which specializes in developing healthy meals for people with slow metabolic health and those in recovery from metabolic disorders. Fuzhou Meida recently opened its restaurant in Fuzhou city, Fujian Province. The restaurant features an open kitchen and adopts a modern Chinese style, offering a variety of modern Chinese healthy light meals and metabolism-boosting meal sets. The Company plans to gradually establish additional branches in key cities across China, including Beijing, Shanghai, Guangzhou, and other southeastern coastal regions.
Tenet-Jove Disposal Group conducts three other business segments. First, developing, manufacturing, and distributing specialized fabrics, textiles, and other by-products derived from an indigenous Chinese plant Apocynum Venetum, known in Chinese as “Luobuma” or “Bluish Dogbane,” as well as Luobuma raw materials processing; this segment is conducted through our wholly owned subsidiary, Tenet-Jove. Second, planting, processing and distributing green and organic agricultural produce, growing and cultivation of yew trees, as well as planting fast-growing bamboo willows and scenic greening trees; this segment is conducted through Qingdao Zhihesheng and Guangyuan. Third, providing domestic air and overland freight forwarding services by outsourcing these services to a third party; this segment is conducted through Zhisheng Freight. Meanwhile, Wintus is engaged in producing, processing and distributing agricultural products, such as silk, silk fabrics and fresh fruit. The business segments conducted by Tenet-Jove Disposal Group and Wintus were reclassified as discontinued operations. The assets and liabilities of the Tenet-Jove Disposal Group and Wintus have been reclassified as “assets of discontinued operations” and “liabilities of discontinued operations” within current and non-current assets and liabilities, respectively, on the unaudited condensed consolidated balance sheet as of March 31, 2025 and the consolidated balance sheet as of June 30, 2024. The results of operations of Tenet-Jove Disposal Group and Wintus have been reclassified to “net income (loss) from discontinued operations” in the unaudited condensed consolidated statements of loss and comprehensive loss for the nine and three months ended March 31, 2025 and 2024.
Financing Activities
On June 16, 2021, the Company entered into a securities purchase agreement pursuant to which the Company issued an unsecured convertible promissory note with a one-year maturity term to an institutional accredited investor, Streeterville Capital, LLC (“Investor”). The note had an original principal amount of US$3,170,000 and Investor gave consideration of US$3.0 million, reflecting original issue discount of US$150,000 and Investor’s legal fee of US$20,000. Interest accrues on the outstanding balance of the note at 6% per annum. The Company has received the principal in full from the Investor and used the proceeds for general working capital purposes. On September 7, 2022, the Company signed an extension amendment with the Investor to extend the maturity date to June 17, 2023. On October 21, 2022, the Company signed a standstill agreement with the Investor, pursuant to which the Investor would not seek to redeem any portion of the note during the period from October 21, 2022 to January 20, 2023. On January 18, 2023, the Investor re-started the redemption of the notes. On June 15, 2023, the Company signed an extension amendment with the Investor to extend the maturity date to June 17, 2024. On December 21, 2023, the Company entered into a preliminary agreement with the Investor, pursuant to which the Investor would not seek repayment of any portion of the note during the period from December 22, 2023 to April 16, 2024. On June 11, 2024, the Company signed an extension amendment with the Investor to extend the maturity date to June 17, 2025. As of March 31, 2025, no share of the Company’s common stock under this agreement was issued by the Company to the Investor, and the notes balance was US$4,523,722, with a carrying value of US$4,552,756, net of deferred financing costs of US$29,034 was recorded in the accompanying unaudited condensed consolidated balance sheets as of March 31, 2025.
| 53 |
On July 16, 2021, the Company entered into another securities purchase agreement with the Investor, pursuant to which the Company issued the Investor two unsecured convertible promissory notes each with a one-year maturity term. The first convertible promissory note had an original principal amount of US$3,170,000 and the Investor gave consideration of US$3.0 million, reflecting original issue discount of US$150,000 and Investor’s legal fee of US$20,000. The second convertible promissory note has the original principal amount of US$4,200,000 and Investor gave consideration of US$4.0 million, reflecting original issue discount of US$200,000. Interest accrues on the outstanding balance of the Notes at 6% per annum. The Company has received the principal in full from the Investor and used the proceeds for general working capital purposes. As of March 31, 2025, the Notes was fully converted and shares of the Company’s common stock totaling 8,112 were issued by the Company to the Investor equaling principal and interests amounted to US$7,472,638.
On August 19, 2021, the Company entered into another securities purchase agreement with the Investor, pursuant to which the Company issued the Investor an unsecured convertible promissory note with a one-year maturity term. The note has an original principal amount of US$10,520,000 and Investor gave consideration of US$10.0 million, reflecting original issue discount of US$500,000 and Investor’s legal fee of US$20,000. Interest accrues on the outstanding balance of the note at 6% per annum. The Company has received the principal in full from the Investor and used the proceeds for general working capital purposes. On September 7, 2022, the Company signed an extension amendment with the Investor to extend the maturity date to August 23, 2023. On October 21, 2022, the Company signed a standstill agreement with the Investor, pursuant to which the Investor will not seek to redeem any portion of the note during the period from October 21, 2022 to January 20, 2023. On June 15, 2023, the Company signed an extension amendment with the Investor to extend the maturity date to August 23, 2024. On December 21, 2023, the Company entered into a preliminary agreement with the Investor, pursuant to which the Investor would not seek repayment of any portion of the note during the period from December 22, 2023 to April 16, 2024. On June 11, 2024, the Company signed an extension amendment with the Investor to extend the maturity date to August 23, 2025. As of March 31, 2025, shares of the Company’s common stock totaling 1,164,023 were issued by the Company to the Investor equaling principal and interests amounted to US$7,785,719 and cash totaling US$1,050,000 was repaid to the Investor. The notes balance was US$5,217,600, with a carrying value of US$5,355,500, net of deferred financing costs of US$137,900 was recorded in the accompanying unaudited condensed consolidated balance sheets as of March 31, 2025.
On June 20, 2024, the Company entered into a securities purchase agreement with certain non-U.S. investors (the “June 2024 Purchasers”), pursuant to which the Company agreed to sell, and the June 2024 Purchasers agreed to purchase, severally and not jointly, an aggregate of 58,333 shares of common stock of the Company (the “June 2024 Shares”) at an offering price of US$120.00 per share for gross proceeds of up to US$7.0 million. In reliance on the June 2024 Purchasers’ representations to the Company, the June 2024 Shares issued in this offering were not subject to the registration requirements of the Securities Act, pursuant to Regulation S promulgated thereunder. As of June 30, 2024, proceeds of approximately US$6.4 million were received by the Company, and the remaining proceeds were fully received by the Company in July 2024, and all of the June 2024 Shares were issued on July 8, 2024.
On July 11, 2024, the Company entered into an Underwriting Agreement with EF Hutton LLC, as the representative for several underwriters, relating to the underwritten public offering (the “Offering”) of 77,882 shares of common stock at a public offering price of US$25.68 per share, for aggregate gross proceeds of approximately US$2.0 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company granted the underwriters a 45-day option to purchase up to an additional 11,683 shares of the common stock at the public offering price per share, less the underwriting discounts to cover over-allotments, if any. The Offering closed on July 15, 2024, and the 45-day option expired on August 30, 2024. The Offering closed on July 15, 2024, and the 45-day option expired on August 30, 2024. The net proceeds from the Offering were approximately US$1.7 million, after deducting the estimated underwriting discounts and commissions and estimated offering expenses.
| 54 |
On August 22, 2024, the Company entered into a securities purchase agreement (the “SPA”) with 22 purchasers, each an unrelated third party to the Company (collectively, the “August 2024 Purchasers”). Pursuant to the SPA, the August 2024 Purchasers agree to purchase, and the Company agreed to issue and sell to the August 2024 Purchasers, an aggregate of 624,375 shares of the Company’s common stock, par value US$0.001 per share (the “August 2024 Shares”), at a purchase price of US$13.20 per share, and for an aggregate purchase price of US$8,241,750. The SPA, the transaction contemplated thereby, and the issuance of the August 2024 Shares have been approved by the Company’s board of directors. The closing of the transaction contemplated by the SPA took place on September 10, 2024. As of March 31, 2025, proceeds of approximately US$4.7 million were received, and the remaining proceeds are expected to be fully received by June 30, 2025.
On December 24, 2024, the Company entered into a securities purchase agreement with nine non-U.S. investors (the “Purchasers”), pursuant to which the Company agreed to sell, and the December 2024 Purchasers agreed to purchase, severally and not jointly, an aggregate of 15,000,000 shares of common stock of the Company (the “Shares”) at a purchase price of US$2.18 per share for gross proceeds of US$32.7 million. In reliance on the Purchasers’ representations to the Company, the Shares were not subject to the registration requirements of the Securities Act, pursuant to Regulation S promulgated thereunder. The Shares were issued to the Purchasers on January 10, 2025, and the proceeds of approximately US$27.6 million received in April 2025. The remaining proceeds are expected to be fully received by June 30, 2025.
Factors Affecting Financial Performance
We believe that the following factors will affect our financial performance:
Increasing demand for our products – We believe that the increasing demand for our products will have a positive impact on our financial position. We plan to develop new products and expand our distribution network as well as to grow our business through possible mergers and acquisitions of similar or synergetic businesses, all aimed at increasing awareness of our brand, developing customer loyalty, meeting customer demands in various markets and providing solid foundations for our growth. As of the date of this Quarterly Report, however, we do not have any agreements, undertakings or understandings to acquire any such entities and there can be no guarantee that we ever will.
Maintaining effective control of our costs and expenses - Successful cost control depends upon our ability to obtain and maintain adequate material supplies as required by our operations at competitive prices. We will focus on improving our long-term cost control strategies including establishing long-term alliances with certain suppliers to ensure adequate supply is maintained. We will carry forward the economies of scale and advantages from our nationwide distribution network and diversified offerings.
Economic and Political Risks
Our operations are conducted primarily in the PRC and subject to special considerations and significant risks not typically associated with companies operating in North America and/or Western Europe. These include risks with, among others, the political, economic and legal environment and foreign currency exchange. Our results may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversions, remittances abroad, and rates and methods of taxation, among other things.
| 55 |
Critical Accounting Policies and Estimates
The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements as well as the reported amounts of revenue and expenses during the reporting period. Critical accounting policies are those accounting policies that may be material due to the levels of subjectivity and judgment necessary to account for highly uncertain matters or the susceptibility of such matters to change, and that have a material impact on financial condition or operating performance. While we base our estimates and judgments on our experience and on various other factors that we believe to be reasonable under the circumstances, actual results may differ from these estimates under different assumptions or conditions. We believe the following critical accounting policies used in the preparation of our unaudited condensed consolidated financial statements require significant judgments and estimates. For additional information relating to these and other accounting policies, see Note 3 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report.
Use of Estimates
Significant estimates required to be made by management include, but are not limited to, useful lives of property and equipment, and intangible assets, the recoverability of long-lived assets, assessment of expected credit losses for accounts receivable and other current asset, the valuation allowance of deferred taxes and inventory reserves. Actual results could differ from those estimates.
Credit Losses
On July 1, 2023, we adopted Accounting Standards Update 2016-13 “Financial Instruments – Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments,” which replaces the incurred loss methodology with an expected loss methodology that is referred to as the current expected credit loss (“CECL”) methodology. The adoption of the credit loss accounting standard has no material impact on our consolidated financial statements as of the date of adoption.
Our account receivables and other receivables included in other current assets on the unaudited condensed consolidated balance sheets are within the scope of ASC Topic 326. We make estimates of expected credit and collectability trends for the allowance for credit losses based upon assessment of various factors, including historical experience, the age of the accounts receivable and other receivables balances, credit-worthiness of the customers and other debtors, current economic conditions, reasonable and supportable forecasts of future economic conditions, and other factors that may affect its ability to collect from the customers and other debtors. We also provide specific provisions for allowance when facts and circumstances indicate that the receivable is unlikely to be collected.
ASC Topic 326 is also applicable to loans to third parties that are included in the other current assets on the unaudited condensed consolidated balance sheets. Management estimates the allowance for credit losses on loans that do not share similar risk characteristics on an individual basis. The key factors considered when determining the above allowances for credit losses include estimated loan collection schedule, discount rate, and assets and financial performance of the borrowers.
Expected credit losses are recorded as general and administrative expenses on the unaudited condensed consolidated statements of loss and comprehensive loss. After all attempts to collect a receivable have failed, the receivable is written off against the allowance. In the event we recover amounts previously reserved for, we will reduce the specific allowance for credit losses.
| 56 |
Inventories, Net
Inventories, which are stated at the lower of cost or net realizable value, consist of raw materials, work-in-progress, and finished goods related to our products. Net realizable value is the estimated selling price in the normal course of business less any costs to complete and sell products. Cost is determined using the weighted average method. We periodically evaluate our inventory and records an inventory reserve for certain inventories that may not be saleable or whose cost exceeds net realizable value. As of March 31, 2025 and June 30, 2024, the inventory reserve from the continuing operations was nil and US$30,443, respectively. As of March 31, 2025 and June 30, 2024, the inventory reserve from the discontinued operations was both nil.
Revenue Recognition
We generate our revenue primarily through sales of Luobuma products, other agricultural products, healthy meals and rapid diagnostic and other products, as well as providing logistic services and other processing services to external customers in accordance with ASC 606. ASC 606 establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash flows arising from the entity’s contracts to provide goods or services to customers. The core principle requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to be entitled to receive in exchange for those goods or services recognized as performance obligations are satisfied.
With the adoption of ASC 606, “Revenue from Contracts with Customers,” revenue is recognized when all of the following five steps are met: (i) identify the contract(s) with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations; (v) recognize revenue when (or as) each performance obligation is satisfied. The Company has assessed the impact of the guidance by reviewing its existing customer contracts to identify differences that will result from applying the new requirements, including the evaluation of its performance obligations, transaction price, customer payments, transfer of control, and principal versus agent considerations. In accordance with ASC 606, the Company evaluates whether it is appropriate to record the gross amount of product sales and related costs or the net amount earned as commissions. When the Company is a principal, that the Company obtains control of the specified goods or services before they are transferred to the customers, the revenue should be recognized in the gross amount of consideration to which it expects to be entitled in exchange for the specified goods or services transferred. When the Company is an agent and its obligation is to facilitate third parties in fulfilling their performance obligation for specified goods or services, the revenue should be recognized in the net amount for the amount of commission which the Company earns in exchange for arranging for the specified goods or services to be provided by other parties. Based on the assessment, the Company concluded that there was no change to the timing and pattern of revenue recognition for its current revenue streams in scope of Topic 606 and therefore there was no material changes to the Company’s financial statements upon adoption of ASC 606. More specifically, revenue related to our products and services is generally recognized as follows:
Sales of products: We recognized revenue from the sale of products at the point in time when the goods were delivered and title to the goods passed to the customer, provided that there were no uncertainties regarding customer acceptance; persuasive evidence of an arrangement existed; the sales price was fixed or determinable; and collectability was deemed probable.
Revenue from provision of services: The Company merely acts as an agent in these types of services transactions. Revenue from domestic air and overland freight forwarding services was recognized at the point in time upon the performance of services as stipulated in the underlying contract or when commodities were being released from the customer’s warehouse; the service price was fixed or determinable; and collectability was deemed probable.
| 57 |
Fair Value of Financial Instruments
We follow the provisions of ASC 820, “Fair Value Measurements and Disclosures.” ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:
Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.
Level 2 applies to assets or liabilities for which there are inputs, other than quoted prices in level, that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the asset or liability.
The carrying value of financial instruments included in current assets and liabilities approximate their fair values because of the short-term nature of these instruments.
Results of Operations for the Nine Months Ended March 31, 2025 and 2024
Overview
The following table summarizes our results of operations for the nine months ended March 31, 2025 and 2024:
| Nine Months Ended March 31, | Variance | |||||||||||||||
| 2025 | 2024 | Amount | % | |||||||||||||
| Revenue | $ | 259,040 | $ | 459,572 | $ | (200,532 | ) | (43.63 | )% | |||||||
| Cost of revenue | 136,707 | 213,133 | (76,426 | ) | (35.86 | )% | ||||||||||
| Gross profit | 122,333 | 246,439 | (124,106 | ) | (50.36 | )% | ||||||||||
| General and administrative expenses | 5,069,621 | 7,474,070 | (2,404,449 | ) | (32.17 | )% | ||||||||||
| Selling expenses | 88,030 | 157,654 | (69,624 | ) | (44.16 | )% | ||||||||||
| Research and development expenses | 54,602 | 77,811 | (23,209 | ) | (29.83 | )% | ||||||||||
| Loss from operations | (5,089,920 | ) | (7,463,096 | ) | 2,373,176 | (31.80 | )% | |||||||||
| Gain from disposal of a subsidiary | 114,945 | - | 114,945 | 100.00 | % | |||||||||||
| Other income, net | 3,505 | 79,520 | (76,015 | ) | (95.59 | )% | ||||||||||
| Amortization of debt issuance and other costs | (482,664 | ) | (612,072 | ) | 129,408 | (21.14 | )% | |||||||||
| Interest expenses, net | (318,001 | ) | (770,898 | ) | 452,897 | (58.75 | )% | |||||||||
| Loss before income tax benefit from continuing operations | (5,772,135 | ) | (8,766,546 | ) | 2,994,411 | (34.16 | )% | |||||||||
| Benefit for income taxes | (187,854 | ) | (152,646 | ) | (35,208 | ) | 23.07 | % | ||||||||
| Net loss from continuing operations | (5,584,281 | ) | (8,613,900 | ) | 3,029,619 | (35.17 | )% | |||||||||
| Net income (loss) from discontinued operations | (15,874,674 | ) | 4,531,193 | (20,405,867 | ) | (450.34 | )% | |||||||||
| Net loss | $ | (21,458,955 | ) | $ | (4,082,707 | ) | $ | (17,376,248 | ) | 425.61 | % | |||||
| Comprehensive loss attributable to Shineco Inc. | $ | (18,736,751 | ) | $ | (2,199,618 | ) | $ | (16,537,133 | ) | 751.82 | % | |||||
| 58 |
Revenue
Currently, we, through our PRC subsidiaries, have two major business segments from continuing operations. First, developing, producing and distributing innovative rapid diagnostic and other products and related medical devices for the most common diseases; this segment is conducted through Biowin. Second, developing and selling healthy meals for people with slow metabolic health and those in recovery from metabolic disorders; this segment is conducted through Fuzhou Meida.
The following table sets forth the breakdown of our revenue for the nine months ended March 31, 2025 and 2024, respectively:
| Nine Months Ended March 31, | Variance | |||||||||||||||||||||||
| 2025 | % | 2024 | % | Amount | % | |||||||||||||||||||
| Rapid diagnostic and other products | $ | 258,091 | 99.63 | % | $ | 441,927 | 96.16 | % | $ | (183,836 | ) | (41.60 | )% | |||||||||||
| Healthy meal products | 949 | 0.37 | % | 17,645 | 3.84 | % | (16,696 | ) | (94.62 | )% | ||||||||||||||
| Total Amount | $ | 259,040 | 100.00 | % | $ | 459,572 | 100.00 | % | $ | (200,532 | ) | (43.63 | )% | |||||||||||
For the nine months ended March 31, 2025 and 2024, revenue from sales of rapid diagnostic and other products was US$258,091 and US$441,927, respectively, representing a decrease of US$183,836, or 41.60%. The decrease was mainly due to a decline in orders we received from our customers during the nine months ended March 31, 2025.
For the nine months ended March 31, 2025 and 2024, revenue from sales of healthy meal products was US$949 and US$17,645, respectively, representing a decrease of US$16,696, or 94.62%. Due to the low market acceptance and high store maintenance cost, we incurred substantial losses in this business segment. Therefore, the management decided to temporarily suspend healthy meal products business, and revenue from sales of healthy meal products decreased during the nine months ended March 31, 2025.
Cost of Revenue and Related Tax
The following table sets forth the breakdown of the cost of revenue for the nine months ended March 31, 2025 and 2024, respectively:
| Nine Months Ended March 31, | Variance | |||||||||||||||||||||||
| 2025 | % | 2024 | % | Amount | % | |||||||||||||||||||
| Rapid diagnostic and other products | $ | 135,603 | 99.19 | % | $ | 168,023 | 78.84 | % | $ | (32,420 | ) | (19.29 | )% | |||||||||||
| Healthy meal products | 249 | 0.18 | % | 43,169 | 20.25 | % | (42,920 | ) | (99.42 | )% | ||||||||||||||
| Business and sales related tax | 855 | 0.63 | % | 1,941 | 0.91 | % | (1,086 | ) | (55.95 | )% | ||||||||||||||
| Total Amount | $ | 136,707 | 100.00 | % | $ | 213,133 | 100.00 | % | $ | (76,426 | ) | (35.86 | )% | |||||||||||
For the nine months ended March 31, 2025 and 2024, cost of revenue from sales of rapid diagnostic and other products was US$135,603 and US$168,023, respectively, representing a decrease of US$32,420, or 19.29%. The decrease was mainly due to a decline in orders we received from our customers, which was partially offset by the increased stock written off as we wrote off certain damaged inventories during the nine months ended March 31, 2025.
| 59 |
For the nine months ended March 31, 2025 and 2024, cost of revenue from sales of healthy meal products was US$249 and US$43,169, respectively, representing a decrease of US$42,920, or 99.42%, which was due to the temporary suspension of healthy meal products business during the nine months ended March 31, 2025 as mentioned above.
Gross Profit (Loss)
The following table sets forth the breakdown of the gross profit (loss) for the nine months ended March 31, 2025 and 2024, respectively:
| Nine Months Ended March 31, | Variance | |||||||||||||||||||||||
| 2025 | % | 2024 | % | Amount | % | |||||||||||||||||||
| Rapid diagnostic and other products | $ | 121,633 | 99.43 | % | $ | 271,973 | 110.36 | % | $ | (150,340 | ) | (55.28 | )% | |||||||||||
| Healthy meal products | 700 | 0.57 | % | (25,534 | ) | (10.36 | )% | 26,234 | (102.74 | )% | ||||||||||||||
| Total Amount | $ | 122,333 | 100.00 | % | $ | 246,439 | 100.00 | % | $ | (124,106 | ) | (50.36 | )% | |||||||||||
Gross profit from sales of rapid diagnostic and other products decreased by US$150,340, or 55.28%, for the nine months ended March 31, 2025 as compared to the same period in 2024. The decrease in gross profit was due to the decrease in sales, which was partially offset by the increased stock written off as mentioned above during the nine months ended March 31, 2025.
Gross profit from sales of healthy meal products increased by US$26,234, or 102.74%, for the nine months ended March 31, 2025 as compared to the same period in 2024. As mentioned above, the management decided to temporarily suspend healthy meal products business to avoid further losses, hence, gross profit increased during the nine months ended March 31, 2025 as compared to the same period last year.
Expenses
The following table sets forth the breakdown of our operating expenses for the nine months ended March 31, 2025 and 2024, respectively, respectively:
| Nine Months Ended March 31, | Variance | |||||||||||||||||||||||
| 2025 | % | 2024 | % | Amount | % | |||||||||||||||||||
| General and administrative expenses | $ | 5,069,621 | 97.26 | % | $ | 7,474,070 | 96.95 | % | $ | (2,404,449 | ) | (32.17 | )% | |||||||||||
| Selling expenses | 88,030 | 1.69 | % | 157,654 | 2.04 | % | (69,624 | ) | (44.16 | )% | ||||||||||||||
| Research and development expenses | 54,602 | 1.05 | % | 77,811 | 1.01 | % | (23,209 | ) | (29.83 | )% | ||||||||||||||
| Total Amount | $ | 5,212,253 | 100.00 | % | $ | 7,709,535 | 100.00 | % | $ | (2,497,282 | ) | (32.39 | )% | |||||||||||
| 60 |
General and Administrative Expenses
For the nine months ended March 31, 2025, our general and administrative expenses were US$5,069,621, representing a decrease of US$2,404,449, or 32.17%, as compared to the same period in 2024. The decrease was mainly due to the decreased expenses of US$3,024,000 as a result of the forgiveness of the subscription receivable upon settlement of the Company’s legal case; see more details in “Off-Balance Sheet Commitments and Arrangements.” The decrease was also due to decreased professional service fee in relation to the acquisition of Wintus of approximately US$780,000, a decrease in staff compensation in relation to the issuance of restricted shares to the management of approximately US$400,000, a deceased allowance for credit losses and doubtful accounts of approximately US$399,000, as well as decreased general and administrative expenses of approximately US$158,000 by Fuzhou Meida due to the temporary suspension of its business operation as mentioned above. The decrease was partially offset by increased compensation expense of approximately US$2,788,000 in relation to the Company’s legal case; see more details in “Off-Balance Sheet Commitments and Arrangements.”
Selling Expenses
For the nine months ended March 31, 2025, our selling expenses were US$88,030, representing a decrease of US$69,624, or 44.16%, as compared to the same period in 2024. The decrease was mainly due to the implementation of cost control measurements, as we reduced the number of sales personnel and cut down the spending on selling activities during the nine months ended March 31, 2025.
Research and Development Expenses
For the nine months ended March 31, 2025, our research and development expenses were US$54,602, representing a decrease of US$23,209, or 29.83%, as compared to the same period in 2024. The decrease was mainly due to less research and development activities towards products development as we tried to control our costs during the nine months ended March 31, 2025.
Gain from disposal of a subsidiary
On November 20, 2024, the Company entered into an agreement to transfer 100% equity interests in Chongshi to a third party as payment for a loan. See Note 8 to our unaudited condensed consolidated financial statements included elsewhere in this Report. The consideration for this transfer was RMB 8.0 million (approximately US$1.1 million), and the gain from disposal of Chongshi was US$114,945 during the nine months ended March 31, 2025.
Other income, net
For the nine ended March 31, 2025, our net other income was US$3,505, representing a decrease of US$76,015, or 95.59%, as compared to net other income of US$79,520 in the same period in 2024. The decrease in net other income was mainly attributable to other income recognized when certain payables were waived by the creditors during the nine months ended March 31, 2025 as well as decreased rental income and government subsidies received during the nine months ended March 31, 2025.
Amortization of Debt Issuance and Other Costs
For the nine months ended March 31, 2025, our amortization of debt issuance and other costs expenses was US$482,664, representing a decrease of US$129,408, or 21.14%, as compared to amortization of debt issuance and other costs expenses of US$612,072 for the same period in 2024. The decrease was mainly due to the decreased extension fee to be amortized during the nine months ended March 31, 2025 as compared to the same period last year, as our balance of the convertible note decreased, our extension fee decreased when we signed extension amendments with the investor to extend the maturity date of the convertible notes.
| 61 |
Interest Expenses, Net
For the nine months ended March 31, 2025, our net interest expenses were US$318,001, representing a decrease of US$452,897, or 58.75%, as compared to net interest expenses of US$770,898 in the same period in 2024. The decrease in net interest expenses was mainly attributable to the increased interest income generated from loans to third parties and decreased interest expense for convertible notes as a result of the decreased balance of the convertible note, which was partially offset by the increased interest expense accrued for outstanding amount payable in related to the Company’s legal case, see more details in “Off-Balance Sheet Commitments and Arrangements”.
Net Loss from Continuing Operations
Our net loss from continuing operations was US$5,584,281 for the nine months ended March 31, 2025, a decrease of US$3,029,619, or 35.17%, from net loss from continuing operations of US$8,613,900 in the same period in 2024. The decrease in net loss from continuing operations was primarily a result of the decrease in general and administrative expenses and interest expenses.
Net Income from Discontinued Operations
As mentioned above, the Company’s Luobuma, Agricultural Products and Freight Services business segments that are operated by the Tenet-Jove Disposal Group and Wintus are reclassified as discontinued operations on the Company’s unaudited condensed consolidated financial statements. We had a total net income (loss) from discontinued operations of US$(15,874,674) and US$4,531,193 for the nine months ended March 31, 2025 and 2024, respectively.
The summarized operating results of our discontinued operations included in our unaudited condensed consolidated statement of loss and comprehensive loss is as follows:
| Nine Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Revenue | $ | 7,633,705 | $ | 4,849,026 | ||||
| Cost of revenue | 7,303,612 | 4,492,269 | ||||||
| Gross profit | 330,093 | 356,757 | ||||||
| Operating expenses | 8,679,608 | 4,807,689 | ||||||
| Other expenses, net | (8,175,947 | ) | (229,970 | ) | ||||
| Loss before income tax | (16,525,462 | ) | (4,680,902 | ) | ||||
| Benefit for income taxes | (650,788 | ) | (307,393 | ) | ||||
| Net loss from discontinued operations | $ | (15,874,674 | ) | $ | (4,373,509 | ) | ||
| Income on disposal of discontinued operations | - | 8,904,702 | ||||||
| Total net income (loss) from discontinued operations | $ | (15,874,674 | ) | $ | 4,531,193 | |||
Net Loss
Our net loss was US$21,458,955 for the nine months ended March 31, 2025, as compared to a net loss of US$4,082,707 for the same period in 2024. The increase in net loss was primarily a result of the increased net loss from discontinued operation, partially offset by the decreased net loss from continuing operations, as discussed above.
Comprehensive Loss
The comprehensive loss was US$21,417,853 for the nine months ended March 31, 2025, an increase of US$17,440,926 from a comprehensive loss of US$3,976,927 for the nine months ended March 31, 2024. After the deduction of non-controlling interest, the comprehensive loss attributable to us was US$18,736,751 for the nine months ended March 31, 2025, as compared to a comprehensive loss attributable to us in the amount of US$2,199,618 for the nine months ended March 31, 2024. The increase in comprehensive loss was due to the increased net loss from discontinued operations, partially offset by the decreased net loss from continuing operations, as discussed above.
Results of Operations for the Three Months Ended March 31, 2025 and 2024
Overview
The following table summarizes our results of operations for the three months ended March 31, 2025 and 2024:
Three Months Ended March 31, | Variance | |||||||||||||||
| 2025 | 2024 | Amount | % | |||||||||||||
| Revenue | $ | 40,971 | $ | 149,346 | $ | (108,375 | ) | (72.57 | )% | |||||||
| Cost of revenue | 55,082 | 78,193 | (23,111 | ) | (29.56 | )% | ||||||||||
| Gross profit (loss) | (14,111 | ) | 71,153 | (85,264 | ) | (119.83 | )% | |||||||||
| General and administrative expenses | 3,710,940 | 1,081,331 | 2,629,609 | 243.18 | % | |||||||||||
| Selling expenses | 20,113 | 61,216 | (41,103 | ) | (67.14 | )% | ||||||||||
| Research and development expenses | 15,487 | 31,895 | (16,408 | ) | (51.44 | )% | ||||||||||
| Loss from operations | (3,760,651 | ) | (1,103,289 | ) | (2,657,362 | ) | 240.86 | % | ||||||||
| Other income, net | 25,553 | 24,696 | 857 | 3.47 | % | |||||||||||
| Amortization of debt issuance and other costs | (146,976 | ) | (246,015 | ) | 99,039 | (40.26 | )% | |||||||||
| Interest expenses, net | (262,239 | ) | (250,899 | ) | (11,340 | ) | (4.52 | )% | ||||||||
| Loss before income tax benefit from continuing operations | (4,144,313 | ) | (1,575,507 | ) | (2,568,806 | ) | 163.05 | % | ||||||||
| Benefit for income taxes | (62,170 | ) | (51,892 | ) | (10,278 | ) | 19.81 | % | ||||||||
| Net loss from continuing operations | (4,082,143 | ) | (1,523,615 | ) | (2,558,528 | ) | 167.92 | % | ||||||||
| Net loss from discontinued operations | (12,529,001 | ) | (2,845,113 | ) | (9,683,888 | ) | 340.37 | % | ||||||||
| Net loss | $ | (16,611,144 | ) | $ | (4,368,728 | ) | $ | (12,242,416 | ) | 280.23 | % | |||||
| Comprehensive loss attributable to Shineco Inc. | $ | (15,076,328 | ) | $ | (3,367,327 | ) | $ | (11,709,001 | ) | 347.72 | % | |||||
Revenue
Currently, we, through our PRC subsidiaries, have two major business segments from continuing operations. First, developing, producing and distributing innovative rapid diagnostic and other products and related medical devices for the most common diseases; this segment is conducted through Biowin. Second, developing and selling healthy meals for people with slow metabolic health and those in recovery from metabolic disorders; this segment is conducted through Fuzhou Meida.
The following table sets forth the breakdown of our revenue for the three months ended March 31, 2025 and 2024, respectively:
| Three Months Ended March 31, | Variance | |||||||||||||||||||||||
| 2025 | % | 2024 | % | Amount | % | |||||||||||||||||||
| Rapid diagnostic and other products | $ | 40,971 | 100.00 | % | $ | 142,805 | 95.62 | % | $ | (101,834 | ) | (71.31 | )% | |||||||||||
| Healthy meal products | - | - | 6,541 | 4.38 | % | (6,541 | ) | (100.00 | )% | |||||||||||||||
| Total Amount | $ | 40,971 | 100.00 | % | $ | 149,346 | 100.00 | % | $ | (108,375 | ) | (72.57 | )% | |||||||||||
| 62 |
For the three months ended March 31, 2025 and 2024, revenue from sales of rapid diagnostic and other products was US$40,971 and US$142,805, respectively, representing a decrease of US$101,834, or 71.31%. The decrease was mainly due to a decline in orders we received from our customers during the three months ended March 31, 2025.
For the three months ended March 31, 2025 and 2024, revenue from sales of healthy meal products was US$ nil and US$6,541, respectively, representing a decrease of US$6,541, or 100.00%. Due to the low market acceptance and high store maintenance cost, we incurred substantial losses in this business segment. Therefore, the management decided to temporarily suspend healthy meal products business, and revenue from sales of healthy meal products decreased during the three months ended March 31, 2025.
Cost of Revenue and Related Tax
The following table sets forth the breakdown of the cost of revenue for the three months ended March 31, 2025 and 2024, respectively:
| Three Months Ended March 31, | Variance | |||||||||||||||||||||||
| 2025 | % | 2024 | % | Amount | % | |||||||||||||||||||
| Rapid diagnostic and other products | $ | 54,899 | 99.67 | % | $ | 53,878 | 68.90 | % | $ | 1,021 | 1.90 | % | ||||||||||||
| Healthy meal products | - | 0.00 | 23,723 | 30.34 | % | (23,723 | ) | (100.00 | )% | |||||||||||||||
| Business and sales related tax | 183 | 0.33 | % | 592 | 0.76 | % | (409 | ) | (69.09 | )% | ||||||||||||||
| Total Amount | $ | 55,082 | 100.00 | % | $ | 78,193 | 100.00 | % | $ | (23,111 | ) | (29.56 | )% | |||||||||||
For the three months ended March 31, 2025 and 2024, cost of revenue from sales of rapid diagnostic and other products was US$54,899 and US$53,878, respectively, representing an increase of US$1,021, or 1.90%. The increase was mainly due to the increased stock written off as we wrote off certain damaged inventories, which was partially offset by the decline in orders we received from our customers during the three months ended March 31, 2025.
For the three months ended March 31, 2025 and 2024, cost of revenue from sales of healthy meal products was US$ nil and US$23,723, respectively, representing a decrease of US$23,723, or 100.00%, which was due to the temporary suspension of healthy meal products business during the three months ended March 31, 2025 as mentioned above.
Gross Profit (Loss)
The following table sets forth the breakdown of the gross profit (loss) for the three months ended March 31, 2025 and 2024, respectively:
| Three Months Ended March 31, | Variance | |||||||||||||||||||||||
| 2025 | % | 2024 | % | Amount | % | |||||||||||||||||||
| Rapid diagnostic and other products | $ | (14,111 | ) | 100.00 | % | $ | 88,345 | 124.16 | % | $ | (102,456 | ) | (115.97 | )% | ||||||||||
| Healthy meal products | - | - | (17,192 | ) | (24.16 | )% | 17,192 | (100.00 | )% | |||||||||||||||
| Total Amount | $ | (14,111 | ) | 100.00 | % | $ | 71,153 | 100.00 | % | $ | (85,264 | ) | (119.83 | )% | ||||||||||
Gross profit from sales of rapid diagnostic and other products decreased by US$102,456, or 115.97%, for the three months ended March 31, 2025 as compared to the same period in 2024. The decrease in gross profit was due to the decrease in sales as well as the increase in stock written off as mentioned above during the three months ended March 31, 2025.
| 63 |
Gross loss from sales of healthy meal products decreased by US$17,192, or 100.00%, for the three months ended March 31, 2025 as compared to the same period in 2024. As mentioned above, the management decided to temporarily suspend healthy meal products business to avoid further losses, hence, gross loss decreased during the three months ended March 31, 2025 as compared to the same period last year.
Expenses
The following table sets forth the breakdown of our operating expenses for the three months ended March 31, 2025 and 2024, respectively:
| Three Months Ended March 31, | Variance | |||||||||||||||||||||||
| 2025 | % | 2024 | % | Amount | % | |||||||||||||||||||
| General and administrative expenses | $ | 3,710,940 | 99.05 | % | $ | 1,081,331 | 92.07 | % | $ | 2,629,609 | 243.18 | % | ||||||||||||
| Selling expenses | 20,113 | 0.54 | % | 61,216 | 5.21 | % | (41,103 | ) | (67.14 | )% | ||||||||||||||
| Research and development expenses | 15,487 | 0.41 | % | 31,895 | 2.72 | % | (16,408 | ) | (51.44 | )% | ||||||||||||||
| Total Amount | $ | 3,746,540 | 100.00 | % | $ | 1,174,442 | 100.00 | % | $ | 2,572,098 | 219.01 | % | ||||||||||||
General and Administrative Expenses
For the three months ended March 31, 2025, our general and administrative expenses were US$3,710,940, representing an increase of US$2,629,609, or 243.18%, as compared to the same period in 2024. The increase was mainly due to increased compensation expense of approximately US$2,788,000 in relation to the Company’s legal case; see more details in “Off-Balance Sheet Commitments and Arrangements.” The increase was partially offset by the decreased general and administrative expenses of Fuzhou Meida due to the temporary suspension of its business operation, as mentioned above.
Selling Expenses
For the three months ended March 31, 2025, our selling expenses were US$20,113, representing a decrease of US$41,103, or 67.14%, as compared to the same period in 2024. The decrease was mainly due to the implementation of cost control measurements, as we reduced the number of sales personnel and cut down the spending on selling activities during the three months ended March 31, 2025.
Research and Development Expenses
For the three months ended March 31, 2025, our research and development expenses were US$15,487, representing a decrease of US$16,408, or 51.44%, as compared to the same period in 2024. The decrease was mainly due to less research and development activities towards product development, as we tried to control our costs during the three months ended March 31, 2025.
Amortization of Debt Issuance and Other Costs
For the three months ended March 31, 2025, our amortization of debt issuance and other costs expenses was US$146,976, representing a decrease of US$99,039, or 40.26%, as compared to amortization of debt issuance and other costs expenses of US$246,015 for the same period in 2024. The decrease was mainly due to the decreased extension fee to be amortized during the three months ended March 31, 2025 as compared to the same period last year, as our balance of the convertible note decreased, our extension fee decreased when we signed extension amendments with the investor to extend the maturity date of the convertible notes.
| 64 |
Interest Expenses, Net
For the three months ended March 31, 2025, our net interest expenses were US$262,239, representing an increase of US$11,340, or 4.52%, as compared to net interest expenses of US$250,899 in the same period in 2024. The increase in net interest expense was mainly attributable to the increased interest expense accrued for the outstanding amount payable in relation to the Company’s legal case; see more details in “Off-Balance Sheet Commitments and Arrangements.” The increase was partially offset by the increased interest income generated from loans to third parties and decreased interest expense for convertible notes as a result of the decreased balance of the convertible note.
Net Loss from Continuing Operations
Our net loss from continuing operations was US$4,082,143 for the three months ended March 31, 2025, an increase of US$2,558,528, or 167.92%, from net loss from continuing operations of US$1,523,615 in the same period in 2024. The increase in net loss from continuing operations was primarily a result of the increase in general and administrative expenses, partially offset by the decrease in amortization of debt issuance costs.
Net Loss from Discontinued Operations
As mentioned above, the Company’s Luobuma, Agricultural Products and Freight Services business segments that are operated by the Tenet-Jove Disposal Group and Wintus are reclassified as discontinued operations on the Company’s unaudited condensed consolidated financial statements. Net loss from discontinued operations was US$12,529,001 and US$2,845,113 for the three months ended March 31, 2025 and 2024, respectively.
The summarized operating results of our discontinued operations included in our unaudited condensed consolidated statement of loss and comprehensive loss are as follows:
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Revenue | $ | 2,628,318 | $ | 1,202,054 | ||||
| Cost of revenue | 2,575,082 | 1,081,540 | ||||||
| Gross profit | 53,236 | 120,514 | ||||||
| Operating expenses | 4,703,032 | 2,243,316 | ||||||
| Other expenses, net | (8,120,251 | ) | (172,530 | ) | ||||
| Loss before income tax | (12,770,047 | ) | (2,295,332 | ) | ||||
| Benefit for income taxes | (241,046 | ) | 549,781 | |||||
| Net loss from discontinued operations | $ | (12,529,001 | ) | $ | (2,845,113 | ) | ||
| Income on disposal of discontinued operations | - | - | ||||||
| Total net loss from discontinued operations | $ | (12,529,001 | ) | $ | (2,845,113 | ) | ||
Net Loss
Our net loss was US$16,611,144 for the three months ended March 31, 2025, as compared to a net loss of US$4,368,728 for the same period in 2024. The increase in net loss was primarily a result of the increased net loss from discontinued operations and increased net loss from continuing operations, as discussed above.
| 65 |
Comprehensive Loss
The comprehensive loss was US$16,564,456 for the three months ended March 31, 2025, an increase of US$12,163,153 from a comprehensive loss of US$4,401,303 for the three months ended March 31, 2024. After the deduction of non-controlling interest, the comprehensive loss attributable to us was US$15,076,328 for the three months ended March 31, 2025, as compared to a comprehensive loss attributable to us in the amount of US$3,367,327 for the three months ended March 31, 2024. The increase in comprehensive loss was due to the increased net loss from discontinued operations and increased net loss from continuing operations, as discussed above.
Treasury Policies
We have established treasury policies with the objectives of achieving effective control of treasury operations and of lowering cost of funds. Therefore, funding for all operations and foreign exchange exposure have been centrally reviewed and monitored from the top level. To manage our exposure to fluctuations in exchange rates and interest rates on specific transactions and foreign currency borrowings, currency structured instruments and other appropriate financial instruments will be used to hedge material exposure, if any.
Our policy precludes us from entering into any derivative contracts purely for speculative activities. Through our treasury policies, we aim to:
(a) Minimize interest risk
This is accomplished by loan re-financing and negotiation. We will continue to closely monitor the total loan portfolio and compare the loan margin spread under our existing agreements against the current borrowing interest rates under different currencies and new offers from banks.
(b) Minimize currency risk
In view of the current volatile currency market, we will closely monitor the foreign currency borrowings at the company level. As of March 31, 2025 and June 30, 2024, except the above-mentioned convertible note, we did not engage in any foreign currency borrowings or loan contracts.
Liquidity and Capital Resources
We currently finance our business operations primarily through short-term, convertible notes and the sale of our common stock. Our current cash primarily consists of cash on hand and cash in bank, which is unrestricted as to withdrawal and use and is deposited with banks in China.
As of March 31, 2025, we had approximately US$1.7 million in short-term bank loans outstanding. We expect that we will be able to renew all of the existing bank loans upon their maturity based on our past experience and outstanding credit history.
On June 16, 2021, we entered into a securities purchase agreement pursuant to which we issued an unsecured convertible promissory note with a one-year maturity term to an institutional accredited investor Streeterville Capital, LLC (“Investor”). The convertible promissory note has the original principal amount of US$3,170,000 and Investor gave consideration of US$3.0 million, reflecting original issue discount of US$150,000 and Investor’s legal fee of US$20,000. We received principal in full from the Investor. On September 7, 2022, we signed an extension amendment with the Investor to extend the maturity date to June 17, 2023. On October 21, 2022, the Company signed a standstill agreement with the Investor, pursuant to which the Investor would not seek to redeem any portion of the note during the period from October 21, 2022 to January 20, 2023. On January 18, 2023, the Investor re-started the redemption of the notes. On June 15, 2023, the Company signed an extension amendment with the Investor to extend the maturity date to June 17, 2024. On December 21, 2023, the Company entered into a preliminary agreement with the Investor, pursuant to which the Investor would not seek repayment of any portion of the note during the period from December 22, 2023 to April 16, 2024. On June 11, 2024, the Company signed an extension amendment with the Investor to extend the maturity date to June 17, 2025.
| 66 |
On July 16, 2021, we entered into a securities purchase agreement pursuant to which we issued two unsecured convertible promissory notes with a one-year maturity term to the same investor. The first convertible promissory note has an original principal amount of US$3,170,000 and the Investor gave consideration of US$3.0 million, reflecting original issue discount of US$150,000 and Investor’s legal fee of US$20,000. The second convertible promissory note has an original principal amount of US$4,200,000 and the Investor gave consideration of US$4.0 million, reflecting original issue discount of US$200,000.
On August 19, 2021, we entered into a securities purchase agreement pursuant to which we issued an unsecured convertible promissory note with a one-year maturity term to the same investor. The Note has the original principal amount of US$10,520,000 and Investor gave consideration of US$10.0 million, reflecting original issue discount of US$500,000 and Investor’s legal fee of US$20,000. We received principal in full from the Investor and we anticipate using the proceeds for general working capital purposes. On September 7, 2022, the Company signed an extension amendment with the Investor to extend the maturity date to August 23, 2023. On October 21, 2022, the Company signed a standstill agreement with the Investor, pursuant to which the Investor will not seek to redeem any portion of the note during the period from October 21, 2022 to January 20, 2023. On June 15, 2023, the Company signed an extension amendment with the Investor to extend the maturity date to August 23, 2024. On December 21, 2023, the Company entered into a preliminary agreement with the Investor, pursuant to which the Investor would not seek repayment of any portion of the note during the period from December 22, 2023 to April 16, 2024. On June 11, 2024, the Company signed an extension amendment with the Investor to extend the maturity date to August 23, 2025.
For the above-mentioned convertible promissory notes issued, as of March 31, 2025, shares of the Company’s common stock totaling 1,172,135 were issued by the Company to the Investor equaling principal and interests amounted to US$15,258,357, and cash totaling US$1,050,000 was repaid to the Investor. The Notes balance was US$9,741,322, with a carrying value of US$9,908,256, net of deferred financing costs of US$166,934 was recorded in the accompanying unaudited condensed consolidated balance sheets as of March 31, 2025.
On June 20, 2024, the Company entered into a securities purchase agreement with certain non-U.S. investors (the “June 2024 Purchasers”), pursuant to which the Company agreed to sell, and the June 2024 Purchasers agreed to purchase, severally and not jointly, an aggregate of 58,333 shares of common stock of the Company (the “June 2024 Shares”) at an offering price of US$120.00 per share for gross proceeds of up to US$7.0 million. In reliance on the June 2024 Purchasers’ representations to the Company, the June 2024 Shares issued in this offering were not subject to the registration requirements of the Securities Act, pursuant to Regulation S promulgated thereunder. As of June 30, 2024, proceeds of approximately US$6.4 million were received by the Company, and the remaining proceeds were fully received by the Company in July 2024, and all of the June 2024 Shares were issued on July 8, 2024.
On July 11, 2024, the Company entered into an Underwriting Agreement with EF Hutton LLC, as the representative for several underwriters, relating to the underwritten public offering (the “Offering”) of 77,882 shares of the common stock at a public offering price of US$25.68 per share, for aggregate gross proceeds of approximately US$2.0 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company granted the underwriters a 45-day option to purchase up to an additional 11,683 shares of the common stock at the public offering price per share, less the underwriting discounts to cover over-allotments, if any. The Offering closed on July 15, 2024, and the 45-day option expired on August 30, 2024. The Offering closed on July 15, 2024, and the 45-day option expired on August 30, 2024. The net proceeds from the Offering were approximately US$1.7 million, after deducting the estimated underwriting discounts and commissions and estimated offering expenses.
On August 22, 2024, the Company entered into a securities purchase agreement (the “SPA”) with 22 purchasers, each an unrelated third party to the Company (collectively, the “August 2024 Purchasers”). Pursuant to the SPA, the August 2024 Purchasers agree to purchase, and the Company agreed to issue and sell to the August 2024 Purchasers, an aggregate of 624,375 shares of the Company’s common stock, par value US$0.001 per share (the “August 2024 Shares”), at a purchase price of US$13.20 per share, and for an aggregate purchase price of US$8,241,750. The SPA, the transaction contemplated thereby, and the issuance of the August 2024 Shares have been approved by the Company’s board of directors. The closing of the transaction contemplated by the SPA took place on September 10, 2024. As of March 31, 2025, proceeds of approximately US$4.7 million were received, and the remaining proceeds are expected to be fully received by June 30, 2025.
| 67 |
On December 24, 2024, the Company entered into a securities purchase agreement with nine non-U.S. investors (the “December 2024 Purchasers”), pursuant to which the Company agreed to sell, and the December 2024 Purchasers agreed to purchase, severally and not jointly, an aggregate of 15,000,000 shares of common stock of the Company (the “Shares”) at a purchase price of US$2.18 per share for gross proceeds of US$32.7 million. In reliance on the Purchasers’ representations to the Company, the Shares were not subject to the registration requirements of the Securities Act, pursuant to Regulation S promulgated thereunder. The Shares were issued to the December 2024 Purchasers on January 10, 2025, and the proceeds of approximately US$27.6 million were received in April 2025. The remaining proceeds are expected to be fully received by June 30, 2025.
As disclosed in the Company’s unaudited condensed consolidated financial statements, the Company had recurring net losses from continuing operations of US$5.6 million and US$8.6 million, and continuing cash outflow of US$2.6 million and US$2.3 million from operating activities for the nine months ended March 31, 2025 and 2024, respectively. As of March 31, 2025 and June 30, 2024, the Company had accumulated a deficit of US$73.1 million and US$54.3 million, and as of March 31, 2025, the Company had negative working capital of US$13.7 million. The Company’s management believes these factors raise substantial doubt about the Company’s ability to continue as a going concern for the next twelve months. In assessing the Company’s going concern, the Company’s management monitors and analyzes the Company’s cash on-hand and its ability to generate sufficient revenue sources in the future to support its operating and capital expenditure commitments. The Company’s liquidity needs are to meet its working capital requirements, operating expenses and capital expenditure obligations. Direct offering and debt financing have been utilized to finance the working capital requirements of the Company. The continuation of the Company as a going concern through the next twelve months is dependent on the continued financial support from its stockholders. The Company’s management believes that the Company’s current access to loans, equity financing as well as financial support from its stockholders will be sufficient to meet its working capital needs for at least the next 12 months. The Company intends to continue to carefully execute its growth plans and manage market risk. If the Company fails to satisfy the Nasdaq Stock Market LLC’s (“Nasdaq”) continued listing requirements, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist its common stock. Any continuing failure to remain in compliance with Nasdaq’s continued listing standards and any subsequent failure to timely resume compliance with Nasdaq’s continued listing standards within the applicable cure period could have adverse consequences and, among other things, substantially impair the Company’s ability to raise additional funds and could result in a loss of institutional investor interest and fewer development opportunities for the Company.
| 68 |
Working Capital
The following table provides the information about our working capital as of March 31, 2025 and June 30, 2024:
| March 31, 2025 | June 30, 2024 | |||||||
| Current assets | $ | 34,918,780 | $ | 20,903,961 | ||||
| Current liabilities | 48,602,178 | 27,562,855 | ||||||
| Working capital | $ | (13,683,398 | ) | $ | (6,658,894 | ) | ||
The working capital decreased by US$7,024,504, or 105.5%, as of March 31, 2025 from June 30, 2024, primarily as a result of an increase in current liabilities held for discontinued operations, current portion of convertible note and other payables and accrued expenses, partially offset by an increase in current assets held for discontinued operations and other current assets.
Capital Commitments and Contingencies
Capital commitments refer to the allocation of funds for the possible purchase in the near future for fixed assets or investment. Contingency refers to a condition that arises from past transactions or events, the outcome of which will be confirmed only by the occurrence or non-occurrence of uncertain futures events.
As of March 31, 2025 and June 30, 2024, we had no other material capital commitments or contingent liabilities.
Contractual Obligations
The Company has no long-term fixed contractual obligations or commitments other than leases that are disclosed in Note 10 in the notes to our unaudited condensed consolidated financial statements.
Off-Balance Sheet Commitments and Arrangements
On May 29, 2023, the Board of the Company approved that we pledged our property as collateral to guarantee a personal loan of a related party, Zhang Yuying, the legal representative of Tenet-Jove. Based on the memorandum entered between us and Zhang Yuying, Zhang Yuying was expected to repay his loan and release the pledge before May 31, 2024, and we have the right to claim full compensation if the property fails to be released by the due date. On May 23, 2024, Zhang Yuying entered into another supplementary agreement with Guo Weiqing, wherein the parties agreed to extend the due date of the principal amount from May 23, 2024 to May 23, 2025, and the real estate property continued to be pledged until May 23, 2025. If Zhang Yuying fails to repay the loan and the property is executed by the Court, the Company has the right to pursue compensation from Zhang Yuying based on the market value of the property. However, Zhang Yuying was unable to repay the loan to Guo Weiqing due to shortage of fund. On November 20, 2024, the Company entered in a supplementary agreement with Zhang Yuying and Guo Weiqing, pursuant to the agreement, the Company agreed to transfer 100% equity interest of Chongshi to Guo Weiqing or other people designated by him as payment for the loan. The consideration for this transfer was RMB 8.0 million (approximately US$1.1 million), which will be paid by Zhang Yuying to the Company by June 30, 2025.
The Company’s subsidiary, Chongqing Wintus (New Star) Enterprises Group, provided a guarantee amounted to US$685,076 for a bank loan borrowed by Chongqing Yufan Trading Co., Ltd, a related party of the Company until December 28, 2025.
Except for the above-mentioned guarantee, we have not entered into any other financial guarantees or other commitments to guarantee the payment obligations of any third parties. In addition, we have not entered into any derivative contracts that are indexed to our own common stock and classified as stockholders’ equity, or that are not reflected in our unaudited condensed consolidated financial statements.
| 69 |
On October 31, 2024, an individual (the “Plaintiff”) file the Civil Complaint against Life Science and another individual in the Beijing Chaoyang District People’s Court. The Plaintiff alleged that the Company entered into a loan agreement with the Plaintiff on April 15, 2024 to borrow RMB 25.0 million (US$3.4 million) for 90 days with an annual interest rate of 30%. The Company borrowed a total of RMB 15.0 million (US$2.1 million) from the Plaintiff, but did not make repayment according to the loan agreement.
Introduced by a business partner (the “Party A”) of Life Science, Life Science entered into a loan agreement with the Plaintiff on April 15, 2024 (the Party A, Life Science and the Plaintiff are collectively called the “Three Parties”). Pursuant to the loan agreement, Life Science would obtain a loan in the amount of RMB 25.0 million (approximately US$ 3.4 million) with a term of 90 days, at the interest rate of 30.0%, and the loan was to be used exclusively as working capital for Life Science’s future merger and acquisition projects. To prevent the misuse of the loans, the Three Parties orally agreed that the loan would first be transferred by the Plaintiff to the bank accounts of the Party A, and upon the completion of merger and acquisition project, the Party A would then transfer the loan to bank accounts designated by Life Science. While this oral agreement was not explicitly stated in the written agreement, the Three Parties mutually agreed and fully understood their rights and obligations. Upon signing the loan agreement, the Plaintiff transferred a total of RMB 15.0 million (approximately US$2.1 million) to the Party A. However, the Party A failed to transfer RMB 15.0 million (the “Fund”) to the bank accounts designated by Life Science as agreed, resulting in the failure to proceed with the merger and acquisition project. On October 31, 2024, the Plaintiff submitted the Civil Complaint to the Beijing Chaoyang District People’s Court against Life Science and the Party A. The Civil Complaint requested that Life Science and the Party A make the compensation to the Plaintiff for the outstanding loans plus interests and the liquidated damages. However, Life Science contended that the Party A’s unauthorized withholding of the funds constituted a fundamental breach of contract, and the related liability should be borne by the Party A personally. Life Science will vigorously defend itself and plans to initiate legal proceedings against the Party A, demanding the return of the Fund to the Plaintiff and compensation for any losses, including the principal of the loan, interest and other penalty fees. As of March 31, 2025, Life Science recorded approximately RMB 22.0 million (US$3.0 million) payable due to the Plaintiff, including the principal of the loan, interest and other penalty fees.
On November 8, 2024, Zhejiang Shijin Packaging Co., Ltd. (“the Plaintiff”) submitted a civil complaint to the People’s Court of Deqing County, Zhejiang Province (the “Court”) against the Company’s subsidiary Biowin. The complaint requested that Biowin make the compensation to the Plaintiff for the outstanding trade payable plus interests and the litigation fee in this case shall be borne by Biowin. On December 5, 2024, the Court issued a judgement that Biowin shall pay the Plaintiff the outstanding trade payable, the litigation fee, and the interest expense if payments are not made according to the schedule. As of March 31, 2025, Biowin recorded RMB 121,447 (US$16,733) trade account payable due to the Plaintiff, and the compensation claimed by the Plaintiff was approximately RMB 54,723 (US$7,540).
On April 16, 2025, Bank of Jiangsu (“the Plaintiff”) commenced a lawsuit against the Company’s subsidiary, Biowin, in the Jiangsu Changzhou High-Tech Industrial Development Zone People’s Court. The Plaintiff alleged that Biowin entered into a loan agreement with the Plaintiff on June 27, 2024, pursuant to which Biowin obtained a loan in the amount of RMB2,946,000 (US$405,904) with a term from June 27, 2024 to January 20, 2025, at the interest rate of 4.00%. However, Biowin failed to make monthly payment of interests, the Plaintiff, in accordance with the loan contract terms, declared the loan due and payable in advance. The loan was matured on January 20, 2025, but Biowin had not fulfilled its repayment obligations, therefore, the Plaintiff alleged that Biowin breached the loan agreement and seek the repayment of the principal, interests, penalty interests and the litigation fee against Biowin. As of March 31, 2025, Biowin recorded RMB 2,946,000 (US$405,904) loan payable due to the Plaintiff, and the interests and compensation claimed by the Plaintiff was RMB 254,322 (US$35,041).
Cash Flows
The following table provides detailed information about our cash flows for the nine months ended March 31, 2025 and 2024, respectively:
| Nine Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Net cash used in operating activities | $ | (3,120,216 | ) | $ | (3,062,020 | ) | ||
| Net cash used in investing activities | (2,984,442 | ) | (13,939,717 | ) | ||||
| Net cash provided by financing activities | 5,995,816 | 3,184,948 | ||||||
| Effect of exchange rate changes on cash and cash equivalents | 936 | 215,513 | ||||||
| Net decrease in cash, cash equivalents and restricted cash | (107,906 | ) | (13,601,276 | ) | ||||
| Cash, cash equivalents and restricted cash, beginning of the period | 395,036 | 14,166,759 | ||||||
| Cash, cash equivalents and restricted cash, end of the period | $ | 287,130 | $ | 565,483 | ||||
| Less: cash of discontinued operations - ended of the period | (94,395 | ) | (168,712 | ) | ||||
| Cash of continuing operations - ended of the period | $ | 192,735 | $ | 396,771 | ||||
Operating Activities
Net cash used in operating activities during the nine months ended March 31, 2025 was approximately US$3.1 million, consisting of net loss from continuing operations of US$5.6 million, depreciation and amortization expenses of US$1.0 million, accrued interest expense for convertible notes of US$0.5 million, amortization of debt issuance and other costs of US$0.5 million, accrued interest income from third parties of US$0.6 million and net changes in our operating assets and liabilities, which mainly included an increase in other payables and accrued expenses of US$2.0 million, an increase in other current assets of US$0.4 million and net cash used in operating activities from discontinued operations of US$0.5 million.
Net cash used in operating activities during the nine months ended March 31, 2024 was approximately US$3.1 million, consisting of net loss from continuing operations of US$8.6 million, depreciation and amortization expenses of US$1.0 million, forgiveness of subscription receivable of US$3.0 million, common stock issued for management and employees of US$0.5 million, accrued interest expense for convertible notes of US$0.7 million, amortization of debt issuance and other costs of US$0.6 million, and net changes in our operating assets and liabilities, which mainly included an increase in other payables and accrued expenses of US$0.6 million and net cash used in operating activities from discontinued operations of US$0.7 million.
| 70 |
Investing Activities
For the nine months ended March 31, 2025, net cash used in investing activities was US$3.0 million, primarily due to prepayment for business acquisition of US$2.6 million and payment made for loans to third parties of US$0.5 million.
For the nine months ended March 31, 2024, net cash used in investing activities was US$13.9 million, primarily due to disposal of Tenet-Jove of US$13.9 million.
Financing Activities
For the nine months ended March 31, 2025, net cash provided by financing activities amounted to approximately US$6.0 million, due to proceeds from issuance of common stock of US$6.8 million, net cash provided by financing activities from discontinued operations of US$0.5 million, partially offset by repayment of loan from third party of US$0.6 million, repayment of convertible note of US$0.4 million and repayments of advances from related parties of US$0.4 million.
For the nine months ended March 31, 2024, net cash provided by financing activities amounted to approximately US$3.2 million, due to proceeds from issuance of common stock of US$2.0 million, proceeds from short-term loans of US$1.2 million, proceeds from advances from related parties of US$0.6 million and proceeds received from investors for subscription of common stock of US$0.3 million, partially offset by net cash used in)financing activities from discontinued operations of US$0.6 million and repayment of short-term loans of US$0.4 million.
| 71 |
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
As a small reporting company, we are not required to provide the information required by this item.
ITEM 4. CONTROLS AND PROCEDURES
(a) Evaluation of Controls and Procedures
We maintain disclosure controls and procedures designed to provide reasonable assurance that material information required to be disclosed by us in the reports filed or submitted under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and that the information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
Based on our review, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures were not effective at the reasonable assurance level as of the end of the period covered by this Quarterly Report due to following material weaknesses:
| ● | a lack of full-time U.S. GAAP personnel in the accounting department to monitor the recording of the transactions; |
| ● | a lack of segregation of duties for accounting personnel who prepared and reviewed the journal entries; and |
| ● | a lack of inadequate control procedures and policies on pre-loan preliminary credit risk evaluation and loan approval. |
In order to address the above material weaknesses, our management has taken the following steps:
| ● | recruiting sufficient qualified professionals with appropriate levels of knowledge and experience to assist in reviewing and resolving accounting issues in routine or complex transactions. To mitigate the reporting risks, we engaged an outside professional consulting firm to supplement our efforts to improve our internal control over financial reporting; |
| ● | improving the communication between management, board of directors, and the Chief Financial Officer; |
| ● | obtaining proper approval for other significant and non-routine transactions from the board of directors; and |
| ● | implementing stringent written documentation and information to capture the borrower’s credit risk adequately and proper controls and policies on the company’s money lending procedures. |
We are committed to monitoring the effectiveness of these measures and making any changes that are necessary and appropriate.
(b) Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting during the fiscal quarter ended March 31, 2025. Because of its inherent limitations, a system of internal control over financial reporting can provide only reasonable assurance and may not prevent or detect misstatements. Further, because of changes in conditions, effectiveness of internal controls over financial reporting may vary over time. Our system contains self-monitoring mechanisms, and actions are taken to correct deficiencies as they are identified.
| 72 |
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS.
Other than ordinary routine litigation (of which we are not currently involved), we know of no material, existing or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceeding or pending litigation, and there are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial stockholder, is an adverse party or has a material interest adverse to our company except as disclosed in the Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2024.
ITEM 1A. RISK FACTORS.
As a “smaller reporting company,” we are not required to provide the information required by this Item.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
There were no unregistered sales of the Company’s equity securities during the nine months ended March 31, 2025 that were not previously disclosed in reports filed with the SEC.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES.
None.
ITEM 4. MINE SAFETY DISCLOSURES.
Not applicable.
ITEM 5. OTHER INFORMATION.
None.
| 73 |
ITEM 6. EXHIBITS
* Filed herewith.
** This certification is deemed furnished, and not filed, for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.
| 74 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| SHINECO, INC. | ||
| Dated: May 15, 2025 | By: | /s/ Jennifer Zhan |
| Jennifer Zhan | ||
| Chief Executive Officer | ||
| (Principal Executive Officer) | ||
| Dated: May 15, 2025 | By: | /s/ Sai (Sam) Wang |
| Sai (Sam) Wang | ||
| Chief Financial Officer | ||
| (Principal Financial and Accounting Officer) | ||
| 75 |